var title_f14_5_14416="Scabies infant foot 1";
var content_f14_5_14416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules, vesicles, and pustules are present on the sole of the foot of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14416=[""].join("\n");
var outline_f14_5_14416=null;
var title_f14_5_14417="Pneumococcal polysaccharide vaccine (23-valent): Patient drug information";
var content_f14_5_14417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pneumococcal polysaccharide vaccine (23-valent): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     see \"Pneumococcal polysaccharide vaccine (23-valent): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     see \"Pneumococcal polysaccharide vaccine (23-valent): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pneumovax&reg; 23",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pneumo 23&trade;;",
"     </li>",
"     <li>",
"      Pneumovax&reg; 23",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10028885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2706002",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_ppsv.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11882 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14417=[""].join("\n");
var outline_f14_5_14417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210867\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028885\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=related_link\">",
"      Pneumococcal polysaccharide vaccine (23-valent): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=related_link\">",
"      Pneumococcal polysaccharide vaccine (23-valent): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_5_14418="Ultrasound neck vessels";
var content_f14_5_14418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of normal neck vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse ultrasound images of the right neck demonstrate normal anatomy, including the internal jugular vein (blue arrow), common carotid artery (red arrow), sternocleidomastoid muscle (SCM), and thyroid gland (T). B shows collapse of the internal jugular vein when compression is applied with the transducer. The carotid artery is not easily compressed with light probe pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lauren W Averill, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14418=[""].join("\n");
var outline_f14_5_14418=null;
var title_f14_5_14419="Alpha thalassemia variants by gap PCR";
var content_f14_5_14419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Detection of common alpha thalassemias by gap PCR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Detection of the Southeast Asian (SEA) deletion by gap PCR. Lanes 1 and 8: DNA size markers (1 kb ladder). Each patient sample is run in duplicate, with the first lane (lanes 2, 4, and 6) using primers that bridge the normal sequence and the second lane (lanes 3, 5, and 7) using primers that bridge the SEA deletion. Lanes 2 and 3 and lanes 6 and 7: heterozygous SEA deletion. Lanes 4 and 5: normal control. Note that the SEA deletion (660 bp fragment) and the normal sequence (980 bp) are both seen in the subject with heterozygous SEA deletion, whereas only the 980 bp fragment is seen in the normal subject.",
"    <div class=\"footnotes\">",
"     PCR: polymerase chain reaction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14419=[""].join("\n");
var outline_f14_5_14419=null;
var title_f14_5_14420="Monoclonal pattern on SPEP";
var content_f14_5_14420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67685%7EHEME%2F74787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67685%7EHEME%2F74787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monoclonal pattern on serum protein electrophoresis (SPEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Densitometer tracing of these findings reveals a tall, narrow-based peak (red asterisk) of gamma mobility and has been likened to a church spire. The monoclonal band has a densitometric appearance similar to that of albumin (alb) and a reduction in the normal polyclonal gamma band.",
"    <br>",
"     (B) A dense, localized band (red asterisk) representing a monoclonal protein of gamma mobility is seen on serum protein electrophoresis on agarose gel (anode on left).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Kyle, RA, Rajkumar, SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman, L, Ausiello, DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright &copy; 2004 Elsevier.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Normal pattern on serum protein electrophoresis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Looking from left to right on the serum protein electrophoresis, a normal pattern has a large peak representing albumin followed by significantly smaller peaks for alfa-1, alfa-2, beta, and gamma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14420=[""].join("\n");
var outline_f14_5_14420=null;
var title_f14_5_14421="Nitrofurantoin: Patient drug information";
var content_f14_5_14421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nitrofurantoin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     see \"Nitrofurantoin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/21/10581?source=see_link\">",
"     see \"Nitrofurantoin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Furadantin&reg;;",
"     </li>",
"     <li>",
"      Macrobid&reg;;",
"     </li>",
"     <li>",
"      Macrodantin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nitrofurantoin&reg;;",
"     </li>",
"     <li>",
"      Macrobid&reg;;",
"     </li>",
"     <li>",
"      Macrodantin&reg;;",
"     </li>",
"     <li>",
"      Novo-Furantoin;",
"     </li>",
"     <li>",
"      Teva-Nitrofurantoin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat a bladder infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702610",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nitrofurantoin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug caused liver problems before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705181",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 38 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698459",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked if you are on this drug for a long time. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697955",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to black, brown, or yellow.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694332",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix liquid with water, milk, or fruit juice before drinking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10912 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14421=[""].join("\n");
var outline_f14_5_14421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202007\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202008\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027832\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027834\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027833\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027838\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027839\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027841\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027836\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027837\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027842\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027843\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=related_link\">",
"      Nitrofurantoin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/21/10581?source=related_link\">",
"      Nitrofurantoin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_5_14422="Methylprednisolone: Patient drug information";
var content_f14_5_14422=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methylprednisolone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     see \"Methylprednisolone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     see \"Methylprednisolone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-Methapred&reg;;",
"     </li>",
"     <li>",
"      Depo-Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg; Dosepak&trade;;",
"     </li>",
"     <li>",
"      Solu-MEDROL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Depo-Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg;;",
"     </li>",
"     <li>",
"      Methylprednisolone Acetate;",
"     </li>",
"     <li>",
"      Solu-Medrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Addison's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling from autoimmune diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat spinal cord injuries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methylprednisolone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin changes (pimples, stretch marks, slow healing, hair growth).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts or glaucoma with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been exposed to chickenpox and have not had chickenpox or had a chickenpox vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       How you take this drug may change. Read  the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning if taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11181 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14422=[""].join("\n");
var outline_f14_5_14422=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195383\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017998\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018000\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017999\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018004\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018005\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018007\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018002\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018003\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018008\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018009\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=related_link\">",
"      Methylprednisolone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=related_link\">",
"      Methylprednisolone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_5_14423="Methods of weaning from mechanical ventilation";
var content_f14_5_14423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Methods of weaning from mechanical ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14423/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14423/contributors\">",
"     Scott K Epstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14423/contributors\">",
"     Allan Walkey, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14423/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14423/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14423/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14423/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/5/14423/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of mechanical ventilation is a two step process, consisting of readiness testing and weaning:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Readiness testing &ndash; Readiness testing is the evaluation of objective criteria to determine whether a patient might be able to successfully and safely wean from mechanical ventilation.",
"     </li>",
"     <li>",
"      Weaning &ndash; Weaning is the process of decreasing the amount of support that the patient receives from the mechanical ventilator, so the patient assumes a greater proportion of the ventilatory effort. The purpose is to assess the probability that mechanical ventilation can be successfully discontinued. Weaning may involve either an immediate shift from full ventilatory support to a period of breathing without assistance from the ventilator or a gradual reduction in the amount of ventilator support [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Weaning has also been referred to as the discontinuation of mechanical ventilation or liberation from the mechanical ventilator.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who wean successfully have less morbidity, mortality, and resource utilization than patients who require prolonged mechanical ventilation or the reinstitution of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The most successful weaning strategies include a daily assessment of the patient&rsquo;s readiness to wean and the careful use of sedatives [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weaning methods are reviewed here. Assessment of a patient&rsquo;s readiness to wean and the extubation process are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=see_link\">",
"     \"Weaning from mechanical ventilation: Readiness testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link\">",
"     \"Extubation management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17990496\">",
"    <span class=\"h1\">",
"     CHOOSING A WEANING METHOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional methods of weaning include spontaneous breathing trials (SBTs), progressive decreases in the level of pressure support during pressure support ventilation (PSV), and progressive decreases in the number of ventilator-assisted breaths during intermittent mandatory ventilation (IMV). Newer weaning methods include computer-driven automated PSV weaning and early extubation with immediate use of post-extubation noninvasive positive pressure ventilation (NPPV).",
"   </p>",
"   <p>",
"    An SBT refers to a patient breathing through the endotracheal tube either without any ventilator support (eg, through a T-piece (",
"    <a class=\"graphic graphic_figure graphicRef76022 \" href=\"UTD.htm?19/43/20159\">",
"     figure 1",
"    </a>",
"    )) or with minimal ventilator support (eg, a low level of pressure support, automatic tube compensation (ATC), or continuous positive airway pressure (CPAP)). We recommend an SBT as the initial weaning strategy for most patients with acute respiratory failure, rather than the alternative methods. This is based upon clinical experience and empirical studies, which indicate that SBTs are simple, efficient, safe, and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 546 patients receiving mechanical ventilation, 416 patients (76 percent) underwent a successful SBT using a T-piece [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/10\">",
"       10",
"      </a>",
"      ]. Among these patients, 340 patients (82 percent) were successfully extubated within 24 hours. The 130 patients whose SBT was unsuccessful were randomly assigned to wean via daily SBTs (using a T-piece), IMV, or PSV. Patients undergoing daily SBTs were more likely to wean successfully than those who were weaned by IMV or PSV (",
"      <a class=\"graphic graphic_table graphicRef57273 \" href=\"UTD.htm?13/23/13691\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In another trial, 300 patients receiving mechanical ventilation were randomly assigned to receive a daily SBT (via T-piece or 5cm H",
"      <sub>",
"       2",
"      </sub>",
"      O of CPAP) or usual care (weaning at the discretion of the attending physician) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/8\">",
"       8",
"      </a>",
"      ]. The daily SBT group had both a shorter duration of mechanical ventilation (4.5 versus 6 days) and fewer complications of respiratory failure (20 versus 41 percent). Complications of respiratory failure included reintubation, tracheostomy, or prolonged mechanical ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The type of SBT (ie, T-piece, low level of pressure support, ATC, or CPAP) is dictated by local availability and clinician preference, with the caveat that in patients with a small, high resistance ETT (size &le;7.0 mm), low level pressure support or ATC may overcome the added work of breathing imposed by the resistance of the endotracheal tube (ETT). When the SBT is conducted using CPAP, PSV, or ATC, the ventilator&rsquo;s monitoring system and alarms can alert the clinician about significant changes in respiratory rate or minute ventilation, whereas a T-piece does not provide this information. There is no evidence that one SBT method is superior to the others in most mechanically ventilated patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T-piece versus low level PSV &ndash; SBTs using a T-piece were compared to SBTs using low level pressure support in two randomized trials. The first trial found no difference in reintubation rates [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/11\">",
"       11",
"      </a>",
"      ]. The second trial found no difference in the proportions of patients who failed weaning and remained mechanically ventilated, although it was limited by significant methodologic flaws [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T-piece versus CPAP &ndash; A randomized trial compared SBTs using a T-piece to SBTs using 5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O CPAP and found no differences in the reintubation rates [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T-piece versus ATC &ndash; SBTs using a T-piece were compared to SBTs using ATC in a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/14\">",
"       14",
"      </a>",
"      ]. There were no differences in weaning success, which was defined as discontinuation of mechanical ventilation without the need for reintubation or NPPV within 48 hours.",
"     </li>",
"     <li>",
"      ATC versus CPAP &ndash; A randomized trial compared SBTs using ATC to SBTs using CPAP and found no difference in the rate of reintubation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ATC versus PSV &ndash; SBTs using ATC were compared to SBTs using PSV in a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/16\">",
"       16",
"      </a>",
"      ]. There were no differences in the rate of reintubation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2991186\">",
"    <span class=\"h2\">",
"     Overcoming endotracheal tube resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for performing a SBT with minimal ventilator support (eg, ATC, low level pressure support, or CPAP) rather than without ventilator support (eg, T-piece) is that the additional support may overcome the resistance created by the ETT. After intubation, the lumen of the endotracheal tube may narrow considerably, causing resistance equivalent to that of a tube one to four times smaller [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/17\">",
"     17",
"    </a>",
"    ]. It has been postulated that the increased work of breathing imposed by the resistance of the ETT may contribute to weaning intolerance. However, clinical studies in heterogeneous populations of mechanically ventilated patients (ie, not restricted to patients with a small, high resistance ETT) have produced mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized crossover trial of 22 patients who had been mechanically ventilated for an average of four days, there were no differences in the work of breathing during SBTs using a T-piece, low level pressure support, or CPAP [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/18\">",
"       18",
"      </a>",
"      ]. In fact, the work of breathing was higher after removal of the ETT than with any of the SBT methods, indicating that either the resistance of the ETT is negligible or the resistance created by an inflamed upper airway due to intubation can be greater than the resistance of the ETT.",
"     </li>",
"     <li>",
"      These findings were supported by an observational study of 14 patients who had been mechanically ventilated for an average of seven days, which found that the work of breathing was the same through a T-piece and following extubation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies do not give insight into the problem of imposed work as only patients tolerating an SBT were studied. Investigators who have focused on patients with signs of weaning intolerance have found that the imposed work of breathing is a major contributor to failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In a study of patients failing a 30 minute T-piece trial, immediate conversion to PSV at 7 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O for an additional 30 minutes resulted in weaning success in 21 of 31 patients (68 percent), suggesting that the endotracheal tube can contribute to iatrogenic weaning failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2991207\">",
"    <span class=\"h2\">",
"     Duration of a weaning trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged SBT does not appear to be superior to a shorter SBT (ie, 30 minutes). A multicenter trial randomly assigned 526 patients receiving mechanical ventilation to undergo SBTs using a T-piece for either 30 or 120 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/23\">",
"     23",
"    </a>",
"    ]. The rates of weaning failure and re-intubation were virtually identical in both groups, suggesting that",
"    <strong>",
"    </strong>",
"    a 30 minute SBT is sufficient to determine whether mechanical ventilation can be discontinued. However, this trial only examined the first SBT. Thus, it is unknown if 30 minutes is an adequate test for patients who have failed their first SBT.",
"   </p>",
"   <p>",
"    The optimal SBT duration may depend upon the duration of mechanical ventilation, the underlying cause for respiratory failure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the clinical context. As an example, patients who have failed an initial SBT and patients with chronic respiratory failure who have undergone an extended duration of mechanical ventilation may warrant a longer SBT to insure that they are ready for independent breathing. In a study of 75 patients with chronic obstructive pulmonary disease who were ventilated for 15 or more days, the median time to SBT failure was 120 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5553351\">",
"    <span class=\"h1\">",
"     IDENTIFYING WEANING SUCCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the weaning strategy used, the clinician must determine whether weaning was a success or failure. Objective criteria that may indicate weaning failure include tachypnea, respiratory distress (use of accessory muscles, thoracoabdominal paradox, and diaphoresis), hemodynamic changes (tachycardia, hypertension), oxyhemoglobin desaturation, and changes in mental status (somnolence, agitation). Examples of criteria used to identify failed weaning attempts in clinical trials include development of a heart rate greater than 140 beats per minute (or a sustained increase of greater than 20 percent), a respiratory rate greater than 35",
"    <span class=\"nowrap\">",
"     breaths/minute,",
"    </span>",
"    a systolic blood pressure greater than 180 mmHg or less than 90 mmHg, a pulse oxygen saturation less than 90 percent, PaO",
"    <sub>",
"     2",
"    </sub>",
"    less than 50mm Hg, pH less than 7.32, marked diaphoresis, or agitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/10,25\">",
"     10,25",
"    </a>",
"    ]. However, clinicians should also use their clinical judgement at the bedside and not rely solely on these parameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5553376\">",
"    <span class=\"h1\">",
"     DECIDING WHETHER TO EXTUBATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If it is determined that weaning was successful, the decision must be made about whether to remove the ETT. This requires an assessment of whether the patient can protect their airway (ie, has a sufficient cough and adequate level of consciousness), the volume of respiratory secretions, and whether the airway is patent (ie, a cuff leak is present). These issues and the extubation procedure itself are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link\">",
"     \"Extubation management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5553436\">",
"    <span class=\"h1\">",
"     WEANING FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of weaning failure should always be sought. Common causes include the underlying source of the respiratory failure not being fully corrected (with an imbalance between work of breathing and respiratory muscle capacity), volume overload, cardiac dysfunction, neuromuscular weakness, delirium, anxiety, metabolic disturbances,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adrenal insufficiency. Once the likely cause of weaning failure has been identified, it should be corrected and then weaning resumed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9176?source=see_link\">",
"     \"Management of the difficult-to-wean patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal weaning strategy following initial weaning failure is uncertain due to conflicting data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 546 patients receiving mechanical ventilation, the 130 patients who failed an initial spontaneous breathing trial (SBT) were randomly assigned to future weaning via SBTs once daily, SBTs several times daily, pressure support ventilation (PSV), or intermittent mandatory ventilation (IMV) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/10\">",
"       10",
"      </a>",
"      ]. The SBTs were performed using a T-piece or CPAP. Patients undergoing once daily SBTs were more likely to wean successfully than those who were weaned by IMV or PSV (",
"      <a class=\"graphic graphic_table graphicRef57273 \" href=\"UTD.htm?13/23/13691\">",
"       table 1",
"      </a>",
"      ). There was no difference in weaning success when SBTs once daily were compared to SBTs several times daily.",
"     </li>",
"     <li>",
"      In contrast, in another trial of 456 patients receiving mechanical ventilation, 109 patients failed an initial SBT and were randomly assigned to future weaning via SBTs, PSV, or IMV [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/25\">",
"       25",
"      </a>",
"      ]. The SBTs were performed using a T-piece. The weaning duration was significantly shorter with a PSV wean (mean 5.7 days) than with either SBTs (mean 8.5 days) or an IMV wean (mean 9.9 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies clearly demonstrate that IMV should not be used for weaning. This is in accord with physiologic studies demonstrating that the degree of respiratory muscle rest on IMV is not proportional to the level of ventilatory support. &nbsp;The neuromuscular apparatus poorly adapts to changing loads because respiratory muscle contraction during lower levels of IMV is similar during both intervening (ie, unsupported) and mandatory (ie, supported) breaths [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/26\">",
"     26",
"    </a>",
"    ]. This effect can be overcome by adding PSV to the unsupported breaths during synchronized intermittent mandatory ventilation (SIMV) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different outcomes in the two trials are probably related to the different ways in which the SBTs were performed during the trials. In the first trial, patients were extubated if they tolerated a two hour SBT. [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/10\">",
"     10",
"    </a>",
"    ]. The patients were unlikely to develop respiratory muscle fatigue because they were closely monitored and returned to full ventilatory support at the first sign of distress [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast, in the second trial, clinicians could request up to three separate SBTs over a 24 hour period, each lasting two hours, before deciding whether to extubate a patient [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/25\">",
"     25",
"    </a>",
"    ]. It is possible that these very prolonged SBTs using a T-piece resulted in fatigue, a process that can take 24 or more hours to reverse (",
"    <a class=\"graphic graphic_figure graphicRef61693 \" href=\"UTD.htm?17/28/17869\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/29\">",
"     29",
"    </a>",
"    ]. In other words, respiratory fatigue may have slowed the progress of patients weaned via SBTs in the second trial.",
"   </p>",
"   <p>",
"    In our clinical practices, we favor once daily SBTs to wean patients who have failed an initial weaning attempt. However, we return the patients to a supportive mode of mechanical ventilation after a failed SBT, look for and correct reversible causes of weaning intolerance, and reassess their readiness to wean the next day.",
"   </p>",
"   <p>",
"    A strategy of extubation with the immediate application of NPPV has been studied in patients with acute on chronic hypercarbic respiratory failure (eg, COPD) and appears promising. In a meta-analysis of 12 randomized trials (530 patients), extubation to NPPV following a failed SBT reduced mortality (RR 0.55, 95 CI 0.38 to 0.79), ventilator associated pneumonia (RR 0.29, 95% CI 0.19 to 0.45), the duration of mechanical ventilation (-5.64 days, 95% CI -9.50 to -1.77), and the need for tracheostomy (RR 0.16, 95% CI 0.04, 0.75), without an increased rate of reintubation (RR 0.73, 95% CI 0.40 to 1.34) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/30\">",
"     30",
"    </a>",
"    ]. We believe that this approach may be considered in patients with COPD or chronic hypercarbic respiratory failure who do not have difficult airways, excessive secretions, or an impaired mental status, but further studies in other patient populations are necessary before it becomes a part of routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3042280\">",
"    <span class=\"h1\">",
"     WEANING PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have shown that clinicians are often overly cautious about initiating weaning [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/6,8,31-33\">",
"     6,8,31-33",
"    </a>",
"    ]. This exposes patients to unnecessarily prolonged mechanical ventilation and its associated risks. Weaning protocols promote the application of evidence-based weaning strategies and multiple trials have demonstrated that weaning protocols are beneficial when compared with usual care. This was illustrated by a meta-analysis of 11 randomized trials (1971 patients), which found that weaning protocols reduced the mean duration of mechanical ventilation by 25 percent, without increasing adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/34\">",
"     34",
"    </a>",
"    ]. However, weaning protocols have not been shown to be superior to usual care in highly staffed, closed ICUs in an academic hospital, suggesting that they may not be beneficial in all settings [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/35\">",
"     35",
"    </a>",
"    ]. This indicates that weaning protocols must be tailored to the patient population to which they will be applied. As an example, a protocol that exclusively focused on determining readiness to wean and conducting SBTs did not improve outcome in neurologic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/36\">",
"     36",
"    </a>",
"    ], but adding a neurologic assessment led to a reduction in the need for reintubation among neurological patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proprietary computerized, closed loop weaning software packages are available that automate weaning by pressure support. The automated weaning program adjusts levels of pressure support to keep patients in a normal range of intermittently-monitored respiratory rate, tidal volume, and exhaled carbon dioxide. Once a patient is stable at a specific level of pressure support, the program automatically reduces the pressure support level and reassesses respiratory stability. Three trials have compared an automated weaning system to usual care with mixed results: two trials demonstrated a shorter duration of mechanical ventilation when automated weaning was compared to usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], one trial found no difference when automated weaning was compared to weaning managed by experienced critical care specialty nurses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14423/abstract/40\">",
"     40",
"    </a>",
"    ], and none of the trials found any harm from automated weaning. Patients whose baseline arterial carbon dioxide tension (PaCO2) is greater than the target range of the weaning software (usually less than 60 mmHg) should not be weaned by automated systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weaning is the process of decreasing the amount of support that the patient receives from the mechanical ventilator, so the patient assumes a greater proportion of the ventilatory effort. The purpose is to assess the probability that mechanical ventilation can be successfully discontinued. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional methods of weaning include spontaneous breathing trials (SBTs), progressive decreases in the level of pressure support during pressure support ventilation (PSV), and progressive decreases in the number of ventilator-assisted breaths during intermittent mandatory ventilation (IMV). An SBT refers to a patient breathing through the endotracheal tube either without any ventilator support (eg, through a T-piece) or with minimal ventilator support (eg, a low level of pressure support, automatic tube compensation (ATC), or continuous positive airway pressure (CPAP)). (See",
"      <a class=\"local\" href=\"#H17990496\">",
"       'Choosing a weaning method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it has been determined that a patient is ready to be weaned:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest weaning via once-daily SBTs, rather than PSV (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17990496\">",
"       'Choosing a weaning method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend weaning via once-daily SBTs, rather than IMV (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17990496\">",
"       'Choosing a weaning method'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients, the SBT may be performed using a T-piece, low level of pressure support (eg, &le;8 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O), ATC, or CPAP (eg, &le;5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O). However, for patients with a small, high resistance endotracheal tube (size &le;7.0 mm), we suggest using low level pressure support or ATC, rather than a T-piece or CPAP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17990496\">",
"       'Choosing a weaning method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An initial SBT of 30 minutes duration is generally sufficient to determine whether mechanical ventilation can be discontinued. For patients who fail their initial SBT, we suggest that subsequent trials be 120 minutes, rather than 30 minutes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17990496\">",
"       'Choosing a weaning method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Weaning by progressive decreases in the level of pressure support (2 to 4 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O per day) during PSV is a reasonable alternative for patients who do not tolerate SBTs. We recommend that IMV alone NOT be used for weaning (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5553436\">",
"       'Weaning failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are NOT in highly staffed, closed ICUs in an academic hospital, we recommend using a weaning protocol (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who are in highly staffed, closed ICUs in an academic hospital, we suggest using a weaning protocol (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3042280\">",
"       'Weaning protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical impression determines whether a patient fails or tolerates weaning. Patients who tolerate the SBT should be considered for extubation. In contrast, patients who fail the SBT should be returned to mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H5553351\">",
"       'Identifying weaning success'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5553376\">",
"       'Deciding whether to extubate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5553436\">",
"       'Weaning failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient fails weaning, the reason for failure should be sought and corrected. Meanwhile, the patient should be assessed daily for readiness to wean. We suggest weaning such patients via once-daily SBTs, rather than SBTs multiple times daily, PSV, or IMV (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5553436\">",
"       'Weaning failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/1\">",
"      Slutsky AS. Mechanical ventilation. American College of Chest Physicians' Consensus Conference. Chest 1993; 104:1833.",
"     </a>",
"    </li>",
"    <li>",
"     Tobin MJ, Jubran A. Weaning from mechanical ventilation. In: Principles and Practice of Mechanical Ventilation, Jubran A, Tobin MJ (Eds), McGraw Hill, New York 2006. p.1185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/3\">",
"      Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/4\">",
"      Coplin WM, Pierson DJ, Cooley KD, et al. Implications of extubation delay in brain-injured patients meeting standard weaning criteria. Am J Respir Crit Care Med 2000; 161:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/5\">",
"      Unroe M, Kahn JM, Carson SS, et al. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. Ann Intern Med 2010; 153:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/6\">",
"      Epstein SK, Ciubotaru RL, Wong JB. Effect of failed extubation on the outcome of mechanical ventilation. Chest 1997; 112:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/7\">",
"      Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008; 371:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/8\">",
"      Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996; 335:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/9\">",
"      Esteban A, Ferguson ND, Meade MO, et al. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med 2008; 177:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/10\">",
"      Esteban A, Frutos F, Tobin MJ, et al. A comparison of four methods of weaning patients from mechanical ventilation. Spanish Lung Failure Collaborative Group. N Engl J Med 1995; 332:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/11\">",
"      Esteban A, Al&iacute;a I, Gordo F, et al. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med 1997; 156:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/12\">",
"      Mati I, Majeri-Kogler V. Comparison of pressure support and T-tube weaning from mechanical ventilation: randomized prospective study. Croat Med J 2004; 45:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/13\">",
"      Jones DP, Byrne P, Morgan C, et al. Positive end-expiratory pressure vs T-piece. Extubation after mechanical ventilation. Chest 1991; 100:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/14\">",
"      Haberth&uuml;r C, Mols G, Elsasser S, et al. Extubation after breathing trials with automatic tube compensation, T-tube, or pressure support ventilation. Acta Anaesthesiol Scand 2002; 46:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/15\">",
"      Cohen JD, Shapiro M, Grozovski E, et al. Extubation outcome following a spontaneous breathing trial with automatic tube compensation versus continuous positive airway pressure. Crit Care Med 2006; 34:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/16\">",
"      Cohen J, Shapiro M, Grozovski E, et al. Prediction of extubation outcome: a randomised, controlled trial with automatic tube compensation vs. pressure support ventilation. Crit Care 2009; 13:R21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/17\">",
"      Wilson AM, Gray DM, Thomas JG. Increases in endotracheal tube resistance are unpredictable relative to duration of intubation. Chest 2009; 136:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/18\">",
"      Mehta S, Nelson DL, Klinger JR, et al. Prediction of post-extubation work of breathing. Crit Care Med 2000; 28:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/19\">",
"      Straus C, Louis B, Isabey D, et al. Contribution of the endotracheal tube and the upper airway to breathing workload. Am J Respir Crit Care Med 1998; 157:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/20\">",
"      DeHaven CB, Kirton OC, Morgan JP, et al. Breathing measurement reduces false-negative classification of tachypneic preextubation trial failures. Crit Care Med 1996; 24:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/21\">",
"      Kirton OC, DeHaven CB, Morgan JP, et al. Elevated imposed work of breathing masquerading as ventilator weaning intolerance. Chest 1995; 108:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/22\">",
"      Ezingeard E, Diconne E, Guyomarc'h S, et al. Weaning from mechanical ventilation with pressure support in patients failing a T-tube trial of spontaneous breathing. Intensive Care Med 2006; 32:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/23\">",
"      Esteban A, Al&iacute;a I, Tobin MJ, et al. Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med 1999; 159:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/24\">",
"      Vitacca M, Vianello A, Colombo D, et al. Comparison of two methods for weaning patients with chronic obstructive pulmonary disease requiring mechanical ventilation for more than 15 days. Am J Respir Crit Care Med 2001; 164:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/25\">",
"      Brochard L, Rauss A, Benito S, et al. Comparison of three methods of gradual withdrawal from ventilatory support during weaning from mechanical ventilation. Am J Respir Crit Care Med 1994; 150:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/26\">",
"      Imsand C, Feihl F, Perret C, Fitting JW. Regulation of inspiratory neuromuscular output during synchronized intermittent mechanical ventilation. Anesthesiology 1994; 80:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/27\">",
"      Jounieaux V, Duran A, Levi-Valensi P. Synchronized intermittent mandatory ventilation with and without pressure support ventilation in weaning patients with COPD from mechanical ventilation. Chest 1994; 105:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/28\">",
"      Laghi F, Cattapan SE, Jubran A, et al. Is weaning failure caused by low-frequency fatigue of the diaphragm? Am J Respir Crit Care Med 2003; 167:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/29\">",
"      Laghi F, D'Alfonso N, Tobin MJ. Pattern of recovery from diaphragmatic fatigue over 24 hours. J Appl Physiol 1995; 79:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/30\">",
"      Burns KE, Adhikari NK, Keenan SP, Meade MO. Noninvasive positive pressure ventilation as a weaning strategy for intubated adults with respiratory failure. Cochrane Database Syst Rev 2010; :CD004127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/31\">",
"      Betbes&eacute; AJ, P&eacute;rez M, Bak E, et al. A prospective study of unplanned endotracheal extubation in intensive care unit patients. Crit Care Med 1998; 26:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/32\">",
"      Saura P, Blanch L, Mestre J, et al. Clinical consequences of the implementation of a weaning protocol. Intensive Care Med 1996; 22:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/33\">",
"      Dries DJ, McGonigal MD, Malian MS, et al. Protocol-driven ventilator weaning reduces use of mechanical ventilation, rate of early reintubation, and ventilator-associated pneumonia. J Trauma 2004; 56:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/34\">",
"      Blackwood B, Alderdice F, Burns K, et al. Use of weaning protocols for reducing duration of mechanical ventilation in critically ill adult patients: Cochrane systematic review and meta-analysis. BMJ 2011; 342:c7237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/35\">",
"      Krishnan JA, Moore D, Robeson C, et al. A prospective, controlled trial of a protocol-based strategy to discontinue mechanical ventilation. Am J Respir Crit Care Med 2004; 169:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/36\">",
"      Namen AM, Ely EW, Tatter SB, et al. Predictors of successful extubation in neurosurgical patients. Am J Respir Crit Care Med 2001; 163:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/37\">",
"      Navalesi P, Frigerio P, Moretti MP, et al. Rate of reintubation in mechanically ventilated neurosurgical and neurologic patients: evaluation of a systematic approach to weaning and extubation. Crit Care Med 2008; 36:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/38\">",
"      Lellouche F, Mancebo J, Jolliet P, et al. A multicenter randomized trial of computer-driven protocolized weaning from mechanical ventilation. Am J Respir Crit Care Med 2006; 174:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/39\">",
"      Stahl C, Dahmen G, Ziegler A, Muhl E. Protocolised automated versus non-protocolised physician-directed weaning from mechanical ventilation: a controlled clinical trial. Intensivemed Prax 2009; 46:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14423/abstract/40\">",
"      Rose L, Presneill JJ, Johnston L, Cade JF. A randomised, controlled trial of conventional versus automated weaning from mechanical ventilation using SmartCare/PS. Intensive Care Med 2008; 34:1788.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1650 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14423=[""].join("\n");
var outline_f14_5_14423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17990496\">",
"      CHOOSING A WEANING METHOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2991186\">",
"      Overcoming endotracheal tube resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2991207\">",
"      Duration of a weaning trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5553351\">",
"      IDENTIFYING WEANING SUCCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5553376\">",
"      DECIDING WHETHER TO EXTUBATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5553436\">",
"      WEANING FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3042280\">",
"      WEANING PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1650|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/43/20159\" title=\"figure 1\">",
"      T piece adapter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/28/17869\" title=\"figure 2\">",
"      Diaphragmatic fatigue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1650|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/23/13691\" title=\"table 1\">",
"      Weaning technique success",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=related_link\">",
"      Extubation management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9176?source=related_link\">",
"      Management of the difficult-to-wean patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=related_link\">",
"      Weaning from mechanical ventilation: Readiness testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_5_14424="Computing the DCI using EPT";
var content_f14_5_14424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Computing the distal contractile integral (DCI) using esophageal pressure topography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The&nbsp;DCI is the measure of the vigor of the distal esophageal contraction utilized in the Chicago Classification. As such it is measured between the proximal and distal pressure troughs for the duration of contraction within this region. To exclude vascular artifacts and intrabolus pressures from the measurement, only pressures greater than 20 mmHg are considered. Hence, the sum of all pressures within the white dotted rectangle in the figure equals the DCI; the units of measurement for the DCI are mmHg-s-cm.",
"    <div class=\"footnotes\">",
"     UES: upper esophageal sphincter; EGJ: esophagogastric junction; s: seconds; DCI:&nbsp;distal contractile integral.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14424=[""].join("\n");
var outline_f14_5_14424=null;
var title_f14_5_14425="Overview of treatment of female infertility";
var content_f14_5_14425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of treatment of female infertility",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14425/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14425/contributors\">",
"     Wendy Kuohung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14425/contributors\">",
"     Mark D Hornstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14425/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14425/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/5/14425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility is a complex disorder with significant medical, psychosocial, and economic aspects [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/1\">",
"     1",
"    </a>",
"    ]. Great strides have been achieved in infertility therapy, with new and effective treatments available in the field of assisted reproductive technology (ART).",
"   </p>",
"   <p>",
"    Once the cause of infertility is identified, therapy aimed at correcting reversible etiologies and overcoming irreversible factors can be implemented. The couple is also counseled on lifestyle modifications to improve fertility, such as smoking cessation, reducing excessive caffeine and alcohol consumption, and appropriate frequency of coitus (every one to two days around the expected time of ovulation) (",
"    <a class=\"graphic graphic_table graphicRef73570 \" href=\"UTD.htm?12/49/13083\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link\">",
"     \"Optimizing natural fertility in couples planning pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further research on causes of infertility and therapeutic modalities is needed to improve the overall success of female infertility treatment. Reducing the cost of therapy, the risk of multiple gestation, and complications such as ovarian hyperstimulation will improve patient access to, and the safety of, infertility therapy.",
"   </p>",
"   <p>",
"    The only absolute contraindications to infertility therapy are contraindication to pregnancy and contraindication to use of the drugs used to enhance fertility. The ethics of restricting infertility therapy for other reasons, such as parental child-rearing ability, severe obesity, life-style issues (tobacco smoking, alcohol consumption), are controversial and beyond the scope of this review [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The parent's marital status, sexual orientation, and HIV status should not be used to deny infertility treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the treatment of female infertility is provided here. The evaluation of female infertility, as well as the causes and treatment of male infertility, are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link\">",
"       \"Causes of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"       \"Evaluation of female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"       \"Causes of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVULATORY DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classifies ovulatory disorders into three groups (",
"    <a class=\"graphic graphic_table graphicRef69734 \" href=\"UTD.htm?29/15/29947\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      WHO class 1 &mdash; Hypogonadotropic hypogonadal anovulation is the least common, occurring in 5 to 10 percent of women. Examples of women in this category are women with hypothalamic amenorrhea from functional etiologies such as excessive exercise or low body weight.",
"     </li>",
"     <li>",
"      WHO class 2 &mdash; Normogonadotropic normoestrogenic anovulation is the most common, accounting for 70 to 85 percent of cases. Women with polycystic ovary syndrome usually fall into this category.",
"     </li>",
"     <li>",
"      WHO class 3 &mdash; Hypergonadotropic hypoestrogenic anovulation occurs in 10 to 30 percent. Women with primary gonadal failure (previously called premature ovarian failure) or gonadal dysgenesis, comprise the majority of these cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperprolactinemic anovulation is a separate category; gonadotropin concentrations in this condition are usually normal or decreased.",
"   </p>",
"   <p>",
"    Oligoovulation unrelated to ovarian failure can usually be treated successfully with ovulation induction; these women achieve fecundability equivalent to that of normal couples (ie, 15 to 25 percent probability of achieving a pregnancy in one menstrual cycle) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/7\">",
"     7",
"    </a>",
"    ]. However, normal fecundability is achieved at the expense of an increased risk of multiple pregnancy.",
"   </p>",
"   <p>",
"    The method of ovulation induction selected should be based upon the underlying cause of anovulation and the efficacy, costs, risks, and potential complications associated with each method as they apply to the individual woman. Options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight modulation",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       Clomiphene",
"      </a>",
"      citrate or other selective estrogen receptor modulators (SERMs)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      or other insulin-sensitizing agents",
"     </li>",
"     <li>",
"      Gonadotropin therapy",
"     </li>",
"     <li>",
"      Aromatase inhibitors",
"     </li>",
"     <li>",
"      Laparoscopic ovarian diathermy",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"       Bromocriptine",
"      </a>",
"      or other dopamine agonist (only in cases of hyperprolactinemia and anovulation)",
"     </li>",
"     <li>",
"      Assisted reproductive technology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these approaches are effective for WHO class 2 patients. WHO class 1 patients respond best to therapy involving lifestyle modification or gonadotropins. Some WHO class 3 patients respond to gonadotropin therapy and in vitro fertilization (IVF), but those who fail require oocyte donation. A synopsis of these therapies is reviewed below; recommendations regarding the choice and dosing of first-line, second-line, and further therapy for ovulation induction according to WHO class are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Weight modulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are far above or below ideal body weight are prone to ovulatory dysfunction and subfertility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/8\">",
"     8",
"    </a>",
"    ]. Weight modulation in these women can enhance fertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     High body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with elevated baseline weight or body mass index (BMI) greater than 27",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    and anovulatory infertility should be advised to lose weight (",
"    <a class=\"graphic graphic_table graphicRef63600 graphicRef74762 \" href=\"UTD.htm?28/43/29361\">",
"     table 3A-B",
"    </a>",
"    )(",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). For obese women with polycystic ovarian syndrome (PCOS), the loss of just 5 to 10 percent of body weight is sufficient to restore ovulation in 55 to 100 percent of these women within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. Weight loss is an inexpensive, low-intervention modality with no side effects and with other health benefits and thus should be a first-line treatment for obese anovulatory women (",
"    <a class=\"graphic graphic_table graphicRef56718 \" href=\"UTD.htm?4/36/4684\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although an improvement in fecundability after weight loss is well documented in obese women with PCOS, the data are not as clear for obese women with regular ovulatory cycles. We recommend weight loss in these women, as well, because of the positive effects of normal BMI on pregnancy and on overall health, and to potentially decrease obstetrical risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link&amp;anchor=H9#H9\">",
"     \"Optimizing natural fertility in couples planning pregnancy\", section on 'Body mass index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Low body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovulatory women with low BMI (less than 17",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63600 graphicRef74762 \" href=\"UTD.htm?28/43/29361\">",
"     table 3A-B",
"    </a>",
"    )(",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), with eating disorders, or strenuous exercise regimens, may develop hypogonadotropic hypogonadism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypothalamic amenorrhea (WHO class 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/14\">",
"     14",
"    </a>",
"    ]. Psychogenic stress may also disrupt the gonadotropin releasing hormone (GnRH) pulse generator and impair ovarian function as a result of reduced pituitary gonadotropin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. Such women should be advised to gain weight, modify diet, and reduce exercise; however, these women are often reluctant to alter their behaviors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"     \"Eating disorders: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of modifying suboptimal behavior was underscored in a randomized trial of women with functional hypothalamic amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/21\">",
"     21",
"    </a>",
"    ]. These women were randomly assigned to either observation or 16 sessions of intrapersonal therapy that assessed eating behavior, nutritional intake, energy expenditure, exercise, and attitudes. The goal of therapy was to correct nutritional deficiencies, energy deficit, and problematic attitudes. Treatment was effective: ovarian function recovered in 87 percent of women who received therapy, but in only 25 percent of women who did not receive the intervention. However, as discussed above, women with eating disorders, other psychiatric conditions, or compulsion to excessive exercise are often unable to change these behaviors after just a brief exposure to counseling.",
"   </p>",
"   <p>",
"    Patients with hypogonadotropic hypogonadism due to eating disorders or intensive exercise who do not respond to behavioral modification may conceive with pulsatile GnRH therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/22\">",
"     22",
"    </a>",
"    ]. Pulsatile GnRH therapy for ovulation induction has been approved by the FDA, but no pharmaceutical company makes it available in the United States at this time. This treatment is available in Europe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of ovulation induction\", section on 'Pulsatile GnRH therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ovulation induction agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clomiphene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate is a selective estrogen receptor modulator (SERM) with both estrogen antagonist and agonist effects that increase gonadotropin release. It is an effective method of inducing ovulation and improving fertility of oligoovulatory women in WHO class 2 (normogonadotropic normoestrogenic ovulatory dysfunction). By comparison, clomiphene is often ineffective in WHO class 1 (hypogonadotropic hypogonadism) and class 3 (hypergonadotropic hypogonadism) patients.",
"   </p>",
"   <p>",
"    Ovulation induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=see_link\">",
"     \"Strategies for improving the efficacy of clomiphene induction of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18552914\">",
"    <span class=\"h3\">",
"     Gonadotropin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    , treatment with gonadotropins requires close hormonal and sonographic monitoring, is expensive, and carries a high risk of multiple gestation. It is used in normogonadotropic (WHO class 2) anovulatory women who have not ovulated or conceived with clomiphene treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insulin sensitizing agents, and in hypogonadotropic (WHO class 1) anovulatory women with hypopituitarism or as second-line therapy in women with hypothalamic amenorrhea. Dosing protocols, monitoring, side effects, and outcomes of gonadotropin therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18552954\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance is commonly observed in women with PCOS. Correction of hyperinsulinemia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    has a beneficial effect in anovulatory women with PCOS because this leads to an increase in menstrual cyclicity and enhanced spontaneous ovulation. However, live birth rates are not as high as those achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    . A consensus group has recommended against the routine use of metformin for ovulation induction except in women with glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the addition of metformin in this setting may help facilitate weight loss and ovulation. In addition, metformin may provide additional metabolic effects that are beneficial for pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link&amp;anchor=H14#H14\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Anovulatory infertility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovulatory WHO 2 patients who have a poor outcome with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    (no ovulation or thin endometrium) may have a better response with aromatase inhibitors. Advantages of these agents over clomiphene include production of fewer follicles and lower estradiol levels (thereby decreasing the risk of multiple gestation) and shorter half-life (50 hours versus 5 days) (resulting in reduced antiestrogen effects on the endometrium and cervical mucus). Because clinical experience with aromatase inhibitors is more limited than that with clomiphene, we view aromatase inhibitors as an alternative ovulation induction agent to first-line therapy with clomiphene. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=see_link\">",
"     \"Ovulation induction with aromatase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aromatase inhibitors in combination with gonadotropins have also emerged as novel ovarian stimulants for performing IVF in women with breast cancer. A presumed advantage of ovarian stimulation with aromatase inhibitors is that the resultant peak estradiol levels are close to those observed in natural cycles.",
"   </p>",
"   <p>",
"    The FDA has not approved aromatase inhibitors for treatment of infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18553001\">",
"    <span class=\"h3\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    citrate, a SERM that is widely used in the secondary chemoprevention of hormone-responsive breast cancer, has also been employed for ovulation induction in PCOS. Tamoxifen has fewer antiestrogen effects on the endometrium and cervix than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    . Nevertheless, a meta-analysis of four randomized trials comparing these drugs found them to be equally effective in inducing ovulation and achieving pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of ovulation induction\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    has also been employed in conjunction with gonadotropins for ovarian stimulation of breast cancer patients undergoing in vitro fertilization (IVF) for embryo banking. It is advantageous in this setting because estradiol exposure is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H3#H3\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Cryopreservation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Laparoscopic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic ovarian drilling by diathermy or laser is a surgical treatment to induce ovulation in anovulatory PCOS patients. For subfertile anovulatory patients with PCOS, a Cochrane review of six randomized trials found similar cumulative ongoing pregnancy rates 6 to 12 months after laparoscopic ovarian drilling and after three to six cycles of ovulation induction with gonadotropins as a primary treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/27\">",
"     27",
"    </a>",
"    ]. However, the rate of multiple pregnancy was considerably lower in women who conceived after ovarian drilling.",
"   </p>",
"   <p>",
"    As laparoscopic ovarian diathermy is invasive and carries more risk for the patient than medical therapy, we reserve its use for patients who fail to conceive with alternative treatments and after other fertility factors have been thoroughly investigated and corrected. This technique is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=see_link\">",
"     \"Laparoscopic surgery for ovulation induction in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , are the treatment of choice for women with hyperprolactinemic anovulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H33#H33\">",
"     \"Overview of ovulation induction\", section on 'Dopamine agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Assisted reproductive technologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligoovulatory women who do not conceive with other fertility treatments may be considered for in vitro fertilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    WHO class 3 patients or women with premature ovarian failure may require oocyte donation by a known or anonymous donor who undergoes controlled ovarian hyperstimulation and oocyte retrieval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TUBAL FACTOR INFERTILITY AND ADHESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We offer surgical reconstruction to young patients with bilateral distal or proximal tubal obstruction who have limited access to IVF. Counseling is provided regarding the success rates of different methods of repair compared with those using the assisted reproductive technologies and on the high risk of ectopic pregnancy. If surgery is successful, this approach has the advantages that additional treatment is not required for each attempt at conception and it allows natural conception.",
"   </p>",
"   <p>",
"    For women with severe tubal disease (bilateral hydrosalpinx, both proximal and distal occlusion, extensive adhesions) and for older women, we recommend IVF as the initial approach because tubal surgery is unlikely to be successful in these patients. Hydrosalpinges should be removed prior to IVF to optimize outcomes. These treatments are discussed briefly below.",
"   </p>",
"   <p>",
"    It is important to make a definitive diagnosis of bilateral proximal tubal occlusion, as HSG may yield false positive results. This is in contrast to distal tubal occlusion, where findings from HSG and laparoscopic tubal lavage typically are concordant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of female infertility\", section on 'Hysterosalpingogram'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unilateral proximal tubal occlusion can be treated medically initially with controlled ovarian hyperstimulation. A retrospective case-controlled study found that controlled ovarian hyperstimulation with IUI in women with unilateral proximal tubal occlusion resulted in pregnancy rates statistically similar to those in patients with unexplained infertility (31 versus 43 percent), while patients with unilateral mid-distal or distal tubal occlusion had significantly lower pregnancy rates (19 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Procedures for improving tubal patency",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9564392\">",
"    <span class=\"h3\">",
"     Distal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for the treatment of tubal factor infertility is most successful in women with distal tubal obstruction. Fimbrioplasty, the lysis of fimbrial adhesions or dilatation of fimbrial strictures, and neosalpingostomy, the creation of a new tubal opening in a distally occluded tube, may be performed via laparotomy or laparoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link&amp;anchor=H7#H7\">",
"     \"Reproductive surgery for female infertility\", section on 'Treatment of distal tubal occlusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9564399\">",
"    <span class=\"h3\">",
"     Proximal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal tubal occlusion may be treated with hysteroscopic or fluoroscopic tubal catheterization or with tubocornual anastomosis by laparotomy (a laparoscopic approach is possible, but requires significant expertise). An advantage of the minimally invasive hysteroscopic approach over fluoroscopy-directed selective salpingography is the capability to perform concomitant laparoscopy with tubal lavage, allowing the clinician both to confirm the diagnosis of proximal occlusion and to treat any coexisting tubal adhesions prior to performing hysteroscopic cannulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tubal catheterization is accomplished with a coaxial catheter system where the outer catheter is directed at the tubal ostium and used to perform a selective salpingogram. If tubal occlusion is observed, the inner catheter is advanced along a guide wire to gently overcome the blockage. In bilateral proximal occlusion, the procedure is successful in 85 percent of tubes and 50 percent of patients conceive, but one third of the tubes re-occlude [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The procedure should be terminated if gentle pressure does not open the tube as over 90 percent of unsuccessful cases are due to true anatomic occlusion from salpingitis isthmica nodosa, chronic salpingitis, or obliterative fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reconstructive surgery for proximal tubal occlusion is not very effective and the risk of subsequent ectopic pregnancy is high (as high as 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/29\">",
"     29",
"    </a>",
"    ]. Therefore, IVF is preferable, if available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link&amp;anchor=H13#H13\">",
"     \"Reproductive surgery for female infertility\", section on 'Treatment of proximal tubal occlusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link&amp;anchor=H18#H18\">",
"     \"Reproductive surgery for female infertility\", section on 'Tubal reanastomosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     In vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVF is a proven method of treatment of tubal factor infertility and has the following advantages and disadvantages compared with tubal reconstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/32\">",
"     32",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Good per cycle success rate (about 30 percent)",
"     </li>",
"     <li>",
"      Less surgically invasive than tubal surgery",
"     </li>",
"     <li>",
"      Can overcome other subfertility factors, if present (eg, male factor, cervical factor, decreased ovarian reserve)",
"     </li>",
"     <li>",
"      Site and extent of tubal damage are not important to outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High per cycle cost and possible need for multiple cycles",
"     </li>",
"     <li>",
"      Need for IVF each time a pregnancy is desired",
"     </li>",
"     <li>",
"      Requires frequent injections and monitoring",
"     </li>",
"     <li>",
"      Increases risk of multiple gestation",
"     </li>",
"     <li>",
"      Increases risk of ovarian hyperstimulation syndrome",
"     </li>",
"     <li>",
"      Slightly higher absolute risk of some adverse perinatal outcome than natural conception",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Salpingectomy for hydrosalpinx",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence from randomized trials that laparoscopic salpingectomy in women with hydrosalpinges improves the outcomes of IVF treatment compared to no surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/33\">",
"     33",
"    </a>",
"    ]. The improvement in pregnancy and live birth rates is likely due to the removal of a source of embryotoxic substances or fluid into the uterus disrupting implantation. It has been hypothesized that the surgical removal of hydrosalpinges might decrease blood supply to the ovaries and compromise ovarian reserve, but this has not been studied. Further investigation is required to assess whether alternative surgical treatments for hydrosalpinx removal (salpingostomy, tubal occlusion, needle drainage of hydrosalpinx at oocyte retrieval) are effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link\">",
"     \"Reproductive surgery for female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ENDOMETRIOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of subfertility in women with endometriosis is approached by identifying and treating reversible causes of infertility followed by sequential application of various therapies: surgical resection of endometriosis, ovulation induction plus intrauterine insemination, and assisted reproductive technologies. We generally use this step-wise approach, except in the setting of multiple infertility factors (eg, significant male factor component, decreased ovarian reserve, pelvic factors) because the presence of multiple factors has a large negative effect on conservative therapy. For these cases, we would probably go straight to IVF rather than apply less resource intensive approaches. A treatment algorithm for infertile patients with early and advanced stage endometriosis is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"     \"Pathogenesis and treatment of infertility in women with endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     UTERINE FACTOR INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of a uterine abnormality is not in and of itself an indication for surgical intervention because there is no uterine abnormality that is always associated with poor reproductive performance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/34\">",
"     34",
"    </a>",
"    ]. However, when a submucous fibroid, endometrial polyp, septate uterus, or uterine synechiae are discovered in the setting of failure to conceive or recurrent pregnancy loss, surgical correction should be considered since there may be a causal association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Leiomyoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between leiomyomas and infertility is controversial. Couples should complete a full infertility evaluation before addressing the role of leiomyomas in their infertility. In general, the best candidates for myomectomy are women with a submucosal fibroid or an intramural fibroid that deforms the uterine cavity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Synechiae, septa, congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine synechiae and septa may be uterine causes of infertility (particularly recurrent pregnancy loss) that may be surgically correctable by hysteroscopic resection. While there is no randomized controlled trial comparing pregnancy outcomes between treated and untreated patients, two retrospective series showed a marked reduction in pregnancy loss after resection of a uterine septum or lysis of adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with severe irreparable uterine defects may require a gestational carrier. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15015?source=see_link\">",
"     \"Surrogate pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Endometrial polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polypectomy can improve fertility in subfertile women with asymptomatic endometrial polyps. This was illustrated in a trial that randomly assigned subfertile women with an endometrial polyp to hysteroscopic polypectomy before IUI or IUI alone and found removal of the polyp significantly improved the pregnancy rate (pregnancy rate 63 percent after polypectomy versus 28 percent with IUI alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/36\">",
"     36",
"    </a>",
"    ]. Based on this trial, and other data from observational studies, we remove endometrial polyps in infertile women, even in the absence of abnormal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Luteal phase defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the scientific definition of luteal phase defect. In the past, it has been defined as a lag in endometrial epithelial maturation as determined by histological analysis of a timed luteal endometrial biopsy. However, there is good evidence that this is not a valid concept because fertile women have a higher prevalence of abnormal endometrial maturation than infertile women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/37\">",
"     37",
"    </a>",
"    ], thus calling into question the association between luteal phase defect and infertility. An alternative approach is to define luteal phase defect based on circulating progesterone concentration. Unfortunately, progesterone is highly pulsatile in the luteal phase; therefore, a single measurement is unlikely to accurately represent integrated progesterone secretion.",
"   </p>",
"   <p>",
"    Clinicians treating women with infertility should avoid making the diagnosis of luteal phase defect until the definition and diagnosis are clarified through further research. Persistent defects of follicular and luteal function that impact fertility are most common in women with oligomenorrhea (cycle length &gt;35 days). Treatment of infertility in these women is best approached by treatment of oligomenorrhea with agents that induce ovulation, rather than with progesterone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link&amp;anchor=H8#H8\">",
"     \"Ovulation induction with clomiphene citrate\", section on 'Clinical indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CERVICAL FACTOR INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical factor infertility is best treated by IUI to bypass cervical factors (eg, scanty or abnormal mucus that might impair fertility). IVF is the next option for patients with cervical factor infertility who fail to conceive with IUI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25351?source=see_link\">",
"     \"Procedure for intrauterine insemination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no strong evidence to support IUI in the absence of ovulation induction agents. A Cochrane review of randomized and controlled trials found IUI was no more effective than timed intercourse for treatment of subfertility attributed to abnormal cervical mucus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14425/abstract/38\">",
"     38",
"    </a>",
"    ]. Subfertility was defined as failure to conceive within one year and cervical mucus abnormality was based upon postcoital testing. The lack of benefit of IUI may be related, at least in part, to the poor prognostic value of postcoital tests for identifying women with abnormal cervical factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of female infertility\", section on 'Postcoital test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     UNEXPLAINED INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples with unexplained infertility have no identifiable etiology of their infertility after comprehensive evaluation; therefore, treatment strategies are empiric.",
"   </p>",
"   <p>",
"    Therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    with IUI may be employed as initial treatment due to the low cost and low risk of side effects. If the patient does not conceive after clomiphene with IUI, gonadotropin injections with IUI or assisted reproductive technologies may be employed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=see_link\">",
"     \"Unexplained infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=see_link\">",
"       \"Patient information: Infertility in women (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=see_link\">",
"       \"Patient information: Infertility in couples (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"       \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"       \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=see_link\">",
"       \"Patient information: Evaluation of the infertile couple (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the cause of infertility is identified, therapy is aimed at correcting reversible etiologies and overcoming irreversible factors. The couple is also counseled on lifestyle modifications to improve fertility, such as smoking cessation, reducing excessive caffeine and alcohol consumption, and appropriate frequency of coitus (",
"      <a class=\"graphic graphic_table graphicRef73570 \" href=\"UTD.htm?12/49/13083\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of ovulatory dysfunction is based upon the underlying cause of anovulation (WHO class 1, 2, or 3 or hyperprolactinemia), and the efficacy, costs, risks, and potential complications associated with each method as they apply to the individual woman. Oligoovulation unrelated to ovarian failure can usually be treated successfully with ovulation induction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ovulatory disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We offer surgical reconstruction to young patients with bilateral proximal or distal tubal obstruction and limited access to IVF, with counseling on the success rates of different methods of repair and on the high risk of ectopic pregnancy. IVF is preferable to surgery in women with severe tubal disease (bilateral hydrosalpinx, both proximal and distal occlusion, extensive adhesions) and for older women, given the proven success of IVF in these patients. Hydrosalpinges should be removed prior to IVF to optimize outcomes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link\">",
"       \"Reproductive surgery for female infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of subfertility in women with endometriosis is approached by identifying and treating reversible causes of infertility followed by a sequential series of steps: surgical resection of endometriosis, ovulation induction plus intrauterine insemination, and assisted reproductive technologies. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Endometriosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical treatment of submucous fibroids, endometrial polyps, septate uterus, or uterine synechiae in the setting of failure to conceive or recurrent pregnancy loss appears to improve ongoing pregnancy rates. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Uterine factor infertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical factor infertility is best treated by bypassing abnormal cervical factors using IUI, generally with ovulation induction agents. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Cervical factor infertility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/1\">",
"      Benyamini Y, Gozlan M, Kokia E. Variability in the difficulties experienced by women undergoing infertility treatments. Fertil Steril 2005; 83:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/2\">",
"      ESHRE Task Force on Ethics and Law, including, Dondorp W, de Wert G, et al. Lifestyle-related factors and access to medically assisted reproduction. Hum Reprod 2010; 25:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/3\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Child-rearing ability and the provision of fertility services. Fertil Steril 2009; 92:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/4\">",
"      Pandey S, Maheshwari A, Bhattacharya S. Should access to fertility treatment be determined by female body mass index? Hum Reprod 2010; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/5\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Access to fertility treatment by gays, lesbians, and unmarried persons. Fertil Steril 2009; 92:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/6\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Human immunodeficiency virus and infertility treatment. Fertil Steril 2004; 82 Suppl 1:S228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/7\">",
"      Collins JA, Wrixon W, Janes LB, Wilson EH. Treatment-independent pregnancy among infertile couples. N Engl J Med 1983; 309:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/8\">",
"      Frisch RE. The right weight: body fat, menarche and ovulation. Baillieres Clin Obstet Gynaecol 1990; 4:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/9\">",
"      Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/10\">",
"      Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/11\">",
"      Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/12\">",
"      Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003; 18:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/13\">",
"      Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994; 61:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/14\">",
"      Snow RC, Barbieri RL, Frisch RE. Estrogen 2-hydroxylase oxidation and menstrual function among elite oarswomen. J Clin Endocrinol Metab 1989; 69:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/15\">",
"      REIFENSTEIN EC Jr. Psychogenic or hypothalamic amenorrhea. Med Clin North Am 1946; 30:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/16\">",
"      Yen SS, Rebar R, Vandenberg G, et al. Pituitary gonadotrophin responsiveness to synthetic LRF in subjects with normal and abnormal hypothalamic-pituitary-gonadal axis. J Reprod Fertil Suppl 1973; 20:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/17\">",
"      Crowley WF Jr, Filicori M, Spratt DI, Santoro NF. The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Prog Horm Res 1985; 41:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/18\">",
"      Berga SL, Girton LG. The psychoneuroendocrinology of functional hypothalamic amenorrhea. Psychiatr Clin North Am 1989; 12:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/19\">",
"      Laughlin GA, Dominguez CE, Yen SS. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1998; 83:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/20\">",
"      Reame NE, Sauder SE, Case GD, et al. Pulsatile gonadotropin secretion in women with hypothalamic amenorrhea: evidence that reduced frequency of gonadotropin-releasing hormone secretion is the mechanism of persistent anovulation. J Clin Endocrinol Metab 1985; 61:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/21\">",
"      Berga SL, Marcus MD, Loucks TL, et al. Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavior therapy. Fertil Steril 2003; 80:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/22\">",
"      Abraham S, Mira M, Llewellyn-Jones D. Should ovulation be induced in women recovering from an eating disorder or who are compulsive exercisers? Fertil Steril 1990; 53:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/23\">",
"      Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/24\">",
"      Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod 2005; 20:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/25\">",
"      Oktay K, Buyuk E, Davis O, et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003; 18:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/26\">",
"      Oktay, K, Buyuk, E, Davis, O, Veeck, L, Rosenwaks, Z. A prospective comparison of tamoxifen alone and tamoxifen-FSH combined protocol for IVF and fertility preservation in breast cancer patients. Fertil Steril 2003; 80:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/27\">",
"      Farquhar C, Vandekerckhove P, Lilford R. Laparoscopic \"drilling\" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2001; :CD001122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/28\">",
"      Farhi J, Ben-Haroush A, Lande Y, Fisch B. Role of treatment with ovarian stimulation and intrauterine insemination in women with unilateral tubal occlusion diagnosed by hysterosalpingography. Fertil Steril 2007; 88:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/29\">",
"      Honor&eacute; GM, Holden AE, Schenken RS. Pathophysiology and management of proximal tubal blockage. Fertil Steril 1999; 71:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/30\">",
"      Pinto AB, Hovsepian DM, Wattanakumtornkul S, Pilgram TK. Pregnancy outcomes after fallopian tube recanalization: oil-based versus water-soluble contrast agents. J Vasc Interv Radiol 2003; 14:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/31\">",
"      Letterie GS, Sakas EL. Histology of proximal tubal obstruction in cases of unsuccessful tubal canalization. Fertil Steril 1991; 56:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/32\">",
"      Practice Committee of the American Society for Reproductive Medicine. Committee opinion: role of tubal surgery in the era of assisted reproductive technology. Fertil Steril 2012; 97:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/33\">",
"      Johnson NP, Mak W, Sowter MC. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev 2004; :CD002125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/34\">",
"      Heinonen PK, Saarikoski S, Pystynen P. Reproductive performance of women with uterine anomalies. An evaluation of 182 cases. Acta Obstet Gynecol Scand 1982; 61:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/35\">",
"      March CM, Israel R. Gestational outcome following hysteroscopic lysis of adhesions. Fertil Steril 1981; 36:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/36\">",
"      P&eacute;rez-Medina T, Bajo-Arenas J, Salazar F, et al. Endometrial polyps and their implication in the pregnancy rates of patients undergoing intrauterine insemination: a prospective, randomized study. Hum Reprod 2005; 20:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/37\">",
"      Coutifaris C, Myers ER, Guzick DS, et al. Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril 2004; 82:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14425/abstract/38\">",
"      Helmerhorst FM, Van Vliet HA, Gornas T, et al. Intra-uterine insemination versus timed intercourse for cervical hostility in subfertile couples. Cochrane Database Syst Rev 2005; :CD002809.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5448 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14425=[""].join("\n");
var outline_f14_5_14425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVULATORY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Weight modulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - High body weight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Low body weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ovulation induction agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clomiphene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18552914\">",
"      - Gonadotropin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18552954\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Metformin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18553001\">",
"      - Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Assisted reproductive technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TUBAL FACTOR INFERTILITY AND ADHESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Procedures for improving tubal patency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9564392\">",
"      - Distal obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9564399\">",
"      - Proximal obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Salpingectomy for hydrosalpinx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ENDOMETRIOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      UTERINE FACTOR INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Synechiae, septa, congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Luteal phase defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CERVICAL FACTOR INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      UNEXPLAINED INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5448|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/49/13083\" title=\"table 1\">",
"      Management infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/15/29947\" title=\"table 2\">",
"      WHO Classification of anovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/22/367\" title=\"table 3A\">",
"      Determining BMI A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/9/157\" title=\"table 3B\">",
"      Determining BMI B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/36/4684\" title=\"table 4\">",
"      Multistep approach treatment infertility PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=related_link\">",
"      Causes of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=related_link\">",
"      Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=related_link\">",
"      Optimizing natural fertility in couples planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=related_link\">",
"      Ovulation induction with aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/42/22180?source=related_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/25/6547?source=related_link\">",
"      Patient information: Infertility in couples (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=related_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=related_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=related_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25351?source=related_link\">",
"      Procedure for intrauterine insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=related_link\">",
"      Strategies for improving the efficacy of clomiphene induction of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15015?source=related_link\">",
"      Surrogate pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=related_link\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_5_14426="Clostridium difficile infection in children: Treatment and prevention";
var content_f14_5_14426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clostridium difficile infection in children: Treatment and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14426/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14426/contributors\">",
"     Michael S Cooperstock, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14426/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/5/14426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/5/14426/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/5/14426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment and prevention of",
"    <em>",
"     Clostridium difficile",
"    </em>",
"    infection in children will be discussed here. The pathogenesis, epidemiology, clinical features, and approach to diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in adults also is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in children depends upon the likelihood of infection versus colonization and the severity of infection. In infants and children, it is often difficult to distinguish colonization from disease. Treatment decisions must be individualized, however, since prompt and appropriate treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    disease improves patient outcomes and minimizes the amount of",
"    <em>",
"     C. difficile",
"    </em>",
"    that is shed into the environment.",
"   </p>",
"   <p>",
"    The treatment guidelines presented below are compatible with recommendations of the American Academy of Pediatrics Committee on Infectious Diseases and largely compatible with the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America guidelines for the treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asymptomatic carrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of asymptomatic carriage is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. In a randomized trial, treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    had no effect on colonization in adult carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/4\">",
"     4",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    was temporarily effective but was associated with increased rates of carriage two months after therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in symptomatic children depends upon the severity of symptoms.",
"   </p>",
"   <p>",
"    In mild cases without systemic signs,",
"    <em>",
"     C. difficile",
"    </em>",
"    -associated diarrhea often resolves with discontinuation of the inducing antibiotic(s) and institution of supportive measures. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Discontinuation of inducing antibiotics'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Supportive care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of children with moderate to severe",
"    <em>",
"     C. difficile",
"    </em>",
"    infection (ie, fever, profuse diarrhea, abdominal tenderness, abdominal distension, leukocytosis, volume depletion, electrolyte imbalance, pseudomembranous colitis) or underlying gastrointestinal tract disease or immune compromise typically involves discontinuation of inducing antibiotics, supportive measures, and antimicrobial therapy. The antimicrobial regimen depends upon the severity of symptoms (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Antimicrobial therapy'",
"    </a>",
"    below). Consultation with specialists in infectious diseases, gastrointestinal disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery may be warranted for children with severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization may be warranted for children with moderate to marked toxicity, dehydration, or poor access to follow-up care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Discontinuation of inducing antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of inducing antibiotics is a critical aspect of treatment. Antecedent antibiotic treatment should be discontinued as soon as possible in patients with clinically significant diarrhea or colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discontinuation of antibiotics may by itself result in improvement or resolution of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. In observational studies of children with",
"    <em>",
"     C. difficile",
"    </em>",
"    diarrhea, one-third to two-thirds of cases resolve with discontinuation of antibiotics and initiation of supportive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In patients who improve after cessation of the inducing antibiotic, specific antimicrobial therapy for",
"    <em>",
"     C. difficile",
"    </em>",
"    infection is unnecessary and, at least in adults, has been associated with an increased risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/7,12,13\">",
"     7,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If ongoing infection requires continued antimicrobial treatment, it may be possible to change to a narrower-spectrum regimen, preferably using antimicrobials less likely to induce",
"    <em>",
"     C. difficile",
"    </em>",
"    disease, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    , macrolides,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , or aminoglycosides. In subgroup analysis from treatment trials in adults, patients not receiving additional antimicrobials improved twice as rapidly and had about one-half as many treatment failures as patients who were continued on antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk of relapse may be increased if inducing antibiotics are given during, or especially after, completion of",
"    <em>",
"     C. difficile",
"    </em>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. It is, therefore, reasonable to continue",
"    <em>",
"     C. difficile",
"    </em>",
"    treatment until a week after the antimicrobial required for a coexisting infection is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care for children with",
"    <em>",
"     C. difficile",
"    </em>",
"    diarrhea involves maintenance of hydration and nutritional status [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimotility drugs and narcotics have been discouraged, because of concerns that they may cause retention of toxins and predispose to complications such as ileus or toxic megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/16\">",
"     16",
"    </a>",
"    ]. However, confirmation of this hypothesis is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D deficiency, which has adverse effects on T-cell and macrophage function, is common in the population. Adults with",
"    <em>",
"     C. difficile",
"    </em>",
"    disease had significantly prolonged clearance of",
"    <em>",
"     C. difficile",
"    </em>",
"    and poorer outcomes if 25OH vitamin D levels were &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/18\">",
"     18",
"    </a>",
"    ]. Although neither causal association for these findings nor benefit from treatment have been demonstrated, some clinicians suggest that vitamin D be measured, and deficiency corrected, in children with",
"    <em>",
"     C. difficile",
"    </em>",
"    disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial treatment for laboratory-confirmed",
"    <em>",
"     C. difficile",
"    </em>",
"    diarrhea may be indicated for children with moderate to severe illness or risk of severe illness (eg, fever, profuse diarrhea, abdominal tenderness, abdominal distension, leukocytosis, volume depletion, electrolyte imbalance, pseudomembranous colitis) or underlying gastrointestinal tract disease or immune compromise, or for persistence of symptoms after inducing antimicrobials have been discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Empiric therapy, pending results of",
"    <em>",
"     C. difficile",
"    </em>",
"    testing, is not routinely recommended, but may be warranted for rapidly deteriorating patients at high risk of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medications that are available to treat",
"    <em>",
"     C. difficile",
"    </em>",
"    in adults appear to have similar efficacy in children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/11,20\">",
"     11,20",
"    </a>",
"    ]. Factors such as severity of illness, potential adverse effects, antimicrobial spectrum, and expense help to guide the choice of agent for the treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    diarrhea in children and adolescents.",
"   </p>",
"   <p>",
"    Available randomized treatment trials have been conducted in adults with mostly nonsevere disease, and are somewhat limited by size and high drop-out. In these studies, oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    and oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    appear to be similarly efficacious, providing symptomatic cure in 70 to 100 percent of patients and bacteriologic cure in at least 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/11,20\">",
"     11,20",
"    </a>",
"    ]. In studies in adults, oral teicoplanin was more efficacious than metronidazole or vancomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/11,20-22\">",
"     11,20-22",
"    </a>",
"    ]. However teicoplanin is relatively expensive and not available in the United States.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"     Fidaxomicin",
"    </a>",
"    is a poorly absorbed macrocyclic antibiotic that is approved for the treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in persons &ge;18 years of age in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/23\">",
"     23",
"    </a>",
"    ]. Its activity is limited to Gram-positive bacteria. In randomized trials in adult patients, the efficacy of fidaxomicin was similar to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    , while reducing the risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/14,20,24-27\">",
"     14,20,24-27",
"    </a>",
"    ]. In secondary analysis of these trials, patients with nonhypervirulent",
"    <em>",
"     C. difficile",
"    </em>",
"    who were treated with fidaxomicin had better outcomes and fewer relapses than those treated with vancomycin (7.8 versus 25.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/14,26,28\">",
"     14,26,28",
"    </a>",
"    ]. Fidaxomicin may ultimately prove to be beneficial for relapsing",
"    <em>",
"     C. difficile",
"    </em>",
"    disease, although additional studies are necessary. The high cost and lack of pediatric approval may limit its use in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100909150\">",
"    <span class=\"h4\">",
"     Moderate or persistent mild disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We consider moderate",
"    <em>",
"     C. difficile",
"    </em>",
"    disease to be characterized by fever, profuse diarrhea, abdominal tenderness, leukocytosis, but no",
"    <strong>",
"    </strong>",
"    abdominal distension, clinical sepsis, hypotension, volume depletion, electrolyte imbalance, pseudomembranous colitis, underlying gastrointestinal tract disease, or immune compromise.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     Metronidazole",
"    </a>",
"    30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by mouth in four divided doses (maximum 2 g per day) is recommended for children and adolescents with moderate",
"    <em>",
"     C. difficile",
"    </em>",
"    disease or persistent disease of lesser severity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,22,29\">",
"     1,22,29",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by mouth in four divided doses (maximum 500 mg per day) is an alternative.",
"   </p>",
"   <p>",
"    In pooled analysis of small randomized trials in adults,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    have similar rates of symptomatic cure (71 versus 79 percent, risk ratio 0.91, 95% CI 0.81-1.03) and bacteriologic cure (53 versus 45 percent, RR 0.85 95% CI 0.62-1.17) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/11\">",
"     11",
"    </a>",
"    ]. In individual trials, they also have similar relapse rates (approximately 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/12,22,30\">",
"     12,22,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     Metronidazole",
"    </a>",
"    has been recommended because it is less expensive than brand name",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    and its use may avoid induction of enterococcal resistance to vancomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. However, generic oral vancomycin (or oral administration of the intravenous form) are now less expensive alternatives, and new evidence indicates that both oral metronidazole and oral vancomycin promote induction of vancomycin-resistant Enterococci [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, metronidazole occasionally causes nausea or neurotoxicity, and bactericidal levels in the colon may be erratic. Furthermore, although resistance is rare, the failure rate for metronidazole has increased since 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100909159\">",
"    <span class=\"h4\">",
"     Severe disease or risk for severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We consider severe",
"    <em>",
"     C. difficile",
"    </em>",
"    disease to be characterized by clinical sepsis, hypotension, volume depletion, abdominal distention, peritonitis, electrolyte imbalance, or pseudomembranous colitis. In adults, white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL",
"    </span>",
"    and albumin &lt;2.5",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    are known to be serious signs; although not studied, they are likely also applicable to children. Patients with underlying intestinal tract disease or immune compromise are at risk for severe",
"    <em>",
"     C. difficile",
"    </em>",
"    disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by mouth in four divided doses, maximum 500 mg per day, for 10 days) is suggested for children and adolescents with severe",
"    <em>",
"     C. difficile",
"    </em>",
"    disease and those who do not respond to initial therapy with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,29,30\">",
"     1,29,30",
"    </a>",
"    ]. Maximal concentrations of vancomycin reach the colon with standard oral dosing because vancomycin is not absorbed. Nonetheless, for the most severely ill patients (eg, those with hypotension or megacolon), some experts believe it is safe and potentially more effective to provide increased doses of vancomycin orally or by nasogastric tube, although there are no supporting data. For this purpose, the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA) guidelines suggest vancomycin 500 mg per dose orally or by nasogastric tube every six hours in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/2\">",
"     2",
"    </a>",
"    ]. The US Food and Drug Administration permits comparable dosing in children, ie, 40",
"    <span class=\"nowrap\">",
"     mg/kg/dose,",
"    </span>",
"    maximum 500",
"    <span class=\"nowrap\">",
"     mg/dose.",
"    </span>",
"    However, neither the safety nor efficacy of enteral vancomycin has been established in children. If the increased dose of vancomycin is used, trough serum levels should be monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, we suggest decreasing to standard doses after the first one or two days.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is preferred to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    for severe disease because reports of treatment failure with metronidazole have been increasing since 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. In addition, in a small randomized trial in adults with severe",
"    <em>",
"     C. difficile",
"    </em>",
"    disease (defined by pseudomembranous colitis, requiring intensive care, or two of the following: age &gt;60 years, fever &gt;38.3&deg;C [101&deg;F], albumin level &lt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    or white blood cell (WBC) count &gt;15,000",
"    <span class=\"nowrap\">",
"     cells/microL),",
"    </span>",
"    the cure rate was higher with vancomycin than metronidazole (97 versus 76 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the results should be interpreted with caution because 12.8 percent of participants were excluded and no intention to treat analysis was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Teicoplanin can be used to treat severe",
"    <em>",
"     C. difficile",
"    </em>",
"    disease in countries where it is available. The optimal dose of teicoplanin for",
"    <em>",
"     C. difficile",
"    </em>",
"    has not been established. In adults, regimens of 50 mg four times daily for three days followed by 100 mg twice daily for four days and 400 mg twice daily for 10 days were used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/21,22,36\">",
"     21,22,36",
"    </a>",
"    ]. There are no data in children.",
"   </p>",
"   <p>",
"    In pooled analysis of two small randomized trials, more patients treated with teicoplanin than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    achieved symptomatic cure (87 versus 73 percent, risk ratio [RR] 1.21, 95% CI 1.0 to 1.5) and bacteriologic cure (82 versus 45 percent, RR 1.8 95% CI 1.2-2.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/11,21,22\">",
"     11,21,22",
"    </a>",
"    ]. Teicoplanin has fewer adverse effects than vancomycin, but it is also more expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/11,37\">",
"     11,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatives to oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    or teicoplanin for children with severe or recalcitrant disease or in whom oral therapy cannot be administered (eg, postoperative, gastrointestinal obstruction, ileus) include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,29,38,39\">",
"     1,29,38,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       Metronidazole",
"      </a>",
"      intravenously as monotherapy for children unable to tolerate the oral route of therapy. However, in a small observational study, mortality was increased among patients treated with intravenous versus oral metronidazole [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       Metronidazole",
"      </a>",
"      intravenously in combination with oral or intraluminal",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      in severe cases. Intraluminal vancomycin may be administered through a nasogastric tube (40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in four divided doses, maximum of 500",
"      <span class=\"nowrap\">",
"       mg/dose).",
"      </span>",
"     </li>",
"     <li>",
"      If ileus is present,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      may be administered per rectum. Rectal vancomycin (500",
"      <span class=\"nowrap\">",
"       mg/100",
"      </span>",
"      mL normal saline) is administered by retention enema four times daily through a Foley catheter, which is clamped for a 30- to 60-minute retention time. Care is required, since perforation is possible. This is continued until there is definite improvement. Although the optimal dose and volume for rectal vancomycin have not been established by clinical trials, and case descriptions vary widely, the recommended volume for adults is 100 mL [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/2\">",
"       2",
"      </a>",
"      ]. Dose adjustments may be required depending on individual circumstances including extent of colonic disease and patient weight. The estimated corresponding volumes for vancomycin retention enemas in children would be 50 mL for children one through three years of age, 75 mL for children three through nine years of age, and 100 mL for children 10 and older. Trough levels should be monitored since vancomycin can be absorbed through inflamed colonic mucosa and cause toxicity, particularly in patients with renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consultation with specialists in infectious diseases, gastrointestinal disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery may be warranted for children with severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual duration of antimicrobial treatment for",
"    <em>",
"     C. difficile",
"    </em>",
"    infection is at least 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    disease is monitored clinically. In patients with mild to moderate disease, fever, systemic manifestations, and frequency of diarrhea generally improve within 24 to 48 hours after initiation of antibiotic therapy, but diarrhea may not fully resolve for four to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/5,41\">",
"     5,41",
"    </a>",
"    ]. Responses may be slower with",
"    <span class=\"nowrap\">",
"     027/BI/NAP1",
"    </span>",
"    infection, and particularly poor in patients with ileus, toxic megacolon, or colonic perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up fecal",
"    <em>",
"     C. difficile",
"    </em>",
"    assays are not recommended because patients often remain colonized with toxin-producing strains after recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,11,21,22\">",
"     1,11,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients remain vulnerable to relapse or reinfection for up to 10 weeks following treatment for",
"    <em>",
"     C. difficile",
"    </em>",
"    infection. (See",
"    <a class=\"local\" href=\"#H80878967\">",
"     'Prevention of recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure is defined by progression of disease after starting treatment, or failure to improve after several days of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/5\">",
"     5",
"    </a>",
"    ]. In a case series of 82 children, treatment failure occurred in 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/43\">",
"     43",
"    </a>",
"    ]. Since coinfections are common in children, those with progression of disease or who fail to improve within three to four days should be reevaluated for other causes of diarrhea. Treatment failure should also raise the possibility of an occult underlying predisposing condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H17#H17\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Occult underlying conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal management for unresponsive",
"    <em>",
"     C. difficile",
"    </em>",
"    infection is not established. If another etiology cannot be identified, patients treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    should be changed to oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    . With severe disease, oral vancomycin combined with oral metronidazole or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/43/44723?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    has been used. Additional or alternative therapies, such as fidaxomycin, may be warranted (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Choice of agent'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Alternative therapies'",
"    </a>",
"    below). In addition, surgical consultation may be necessary for patients with signs of toxic megacolon, peritonitis, or sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80878967\">",
"    <span class=\"h3\">",
"     Prevention of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients remain vulnerable to relapse or reinfection for up to ten weeks following treatment for",
"    <em>",
"     C. difficile",
"    </em>",
"    infection. During this period of vulnerability, important preventive measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antimicrobial treatment should be avoided if possible. If antimicrobial treatment is necessary in a high-risk patient (eg, underlying gastrointestinal disease or immune compromise), oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      can be continued until a week after the antimicrobial has been discontinued. However, there are no data to support or refute this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Discontinuation of inducing antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Good hand hygiene. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Hand hygiene'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Avoidance of proton pump inhibitors, if possible. (See",
"      <a class=\"local\" href=\"#H27380732\">",
"       'Avoidance of proton pump inhibitors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Avoidance of exposure to",
"      <em>",
"       C. difficile",
"      </em>",
"      (by avoiding close contact with infants or persons known to be",
"      <em>",
"       C. difficile",
"      </em>",
"      carriers) and avoidance of hospitalization, if possible.",
"     </li>",
"     <li>",
"      Although not studied, it is prudent to avoid potential animal sources of",
"      <em>",
"       C. difficile",
"      </em>",
"      and uncooked foods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36637750\">",
"    <span class=\"h3\">",
"     Treatment of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of symptoms after completion of antibiotic treatment (either as a relapse or a reinfection with a new strain) may occur in as many as 31 percent of pediatric",
"    <em>",
"     C. difficile",
"    </em>",
"    illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest retesting for other causes if symptoms recur because recurrent diarrhea is not always due to",
"    <em>",
"     C. difficile.",
"    </em>",
"    Other diagnoses should be considered even if a fecal test for",
"    <em>",
"     C. difficile",
"    </em>",
"    is positive, since persistence of",
"    <em>",
"     C. difficile",
"    </em>",
"    is common after effective treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link&amp;anchor=H25#H25\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal management for unresponsive cases or multiple relapses of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection is not established for children or adults. However, review of the literature suggests that very few children have more than two recurrences, regardless of the initial treatment regimen(s). This suggests that seemingly successful but uncontrolled trials of any treatment for pediatric relapsing",
"    <em>",
"     C. difficile",
"    </em>",
"    infection may simply reflect the natural course of the disease.",
"   </p>",
"   <p>",
"    Various regimens that have been used to treat recurrent",
"    <em>",
"     C. difficile",
"    </em>",
"    infection (primarily in adults) include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,44-46\">",
"     1,44-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the first recurrence, retreatment with the same antibiotic that was successful initially for a duration of 10 days.",
"     </li>",
"     <li>",
"      For a second or third recurrence, a trial of oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      given in tapering or pulse fashion. These regimens are discussed separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link&amp;anchor=H11#H11\">",
"       \"Clostridium difficile in adults: Treatment\", section on 'Vancomycin'",
"      </a>",
"      ). Use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      is not recommended for treatment of a second or third recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A two-week course of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      followed by two weeks of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/43/44723?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      or possibly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"       fidaxomicin",
"      </a>",
"      has also been used to treat recurrent disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/43/44723?source=see_link\">",
"       Nitazoxanide",
"      </a>",
"      is available for the treatment of",
"      <em>",
"       Cryptosporidium",
"      </em>",
"      and",
"      <em>",
"       Giardia",
"      </em>",
"      diarrhea in individuals one year of age and older. It is broadly active against most bacterial anaerobes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/47\">",
"       47",
"      </a>",
"      ]. In randomized trials, nitazoxanide produced cure and relapse rates similar to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      for initial treatment of",
"      <em>",
"       C. difficile",
"      </em>",
"      infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. Adult patients unresponsive to, or relapsing after, metronidazole treatment had a 66 percent response to one or more courses of nitazoxanide 500 mg twice per day [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/50\">",
"       50",
"      </a>",
"      ]. Phase III trials are in progress.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       Rifaximin",
"      </a>",
"      is a nonabsorbable, broad-spectrum, rifamycin-class antibiotic with a good safety profile, minimal drug interactions, and high activity against most strains of",
"      <em>",
"       C. difficile",
"      </em>",
"      . It has relatively little effect on the intestinal microbiome [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/51\">",
"       51",
"      </a>",
"      ]. In observational studies, a course of rifaximin after treatment for",
"      <em>",
"       C. difficile",
"      </em>",
"      has been associated with eradication of infection and decreased rates of relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Rifaximin is approved in the United States for treatment of travelers' diarrhea in individuals &ge;12 years of age, and for additional indications in other countries. Phase III trials of rifaximin are ongoing. An important concern is its potential to induce resistance to rifamycins [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. Conversely, prior treatment with a rifamycin increases risk of rifaximin resistance in the infecting strain of",
"      <em>",
"       C. difficile",
"      </em>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/28/15812?source=see_link\">",
"       Fidaxomicin",
"      </a>",
"      has been associated with fewer relapses than other medications when it is used for initial treatment of adults with",
"      <em>",
"       C. difficile",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/14,26,28\">",
"       14,26,28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73645980\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may occasionally be warranted as a life-saving measure for severely ill children with megacolon, colonic perforation, acute abdomen, or septic shock.",
"   </p>",
"   <p>",
"    Death from",
"    <em>",
"     C. difficile",
"    </em>",
"    is rare in children, and there are no published guidelines regarding indications for surgery in this age group. However, a clinical practice guideline for",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in adults from SHEA and IDSA indicates that colectomy may be warranted as a life-saving measure for selected severely ill patients (eg, those with megacolon, colonic perforation, acute abdomen, or septic shock) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/2\">",
"     2",
"    </a>",
"    ]. The guidelines suggest that monitoring serum lactate and peripheral WBC count may be helpful in deciding when to operate because lactate &ge;5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and WBC count &ge;50,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    have been associated with increased perioperative mortality in adults. The SHEA-IDSA guidelines suggest subtotal colectomy with preservation of the rectum if surgical management is necessary for severely ill adults with",
"    <em>",
"     C. difficile",
"    </em>",
"    . Diversion ileostomy may be an alternative to subtotal colectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link&amp;anchor=H24#H24\">",
"     \"Clostridium difficile in adults: Treatment\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The applicability of these recommendations to children must be tempered by the knowledge that colectomy is rarely required (1.2 percent of cases in a multicenter retrospective cohort of hospitalized children [2001-2006] [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/56\">",
"     56",
"    </a>",
"    ]) and that mortality from",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in children is low (1 to 2 percent, compared with approximately 7 percent in adult populations) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternatives to antimicrobial therapy are desirable because antimicrobial treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection can disturb the protective indigenous gastrointestinal flora. Trials of such approaches include toxin binders, immunotherapy, probiotics, and fecal transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Toxin binders",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     C. difficile",
"    </em>",
"    toxins A and B are anionic, which has prompted consideration of anion-binding resins as a possible alternative to antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/57\">",
"     57",
"    </a>",
"    ]. In contrast to antibiotic therapy, resin therapy does not alter the bowel flora and may permit more rapid reconstitution of the normal flora.",
"   </p>",
"   <p>",
"    Tolevamer is a nonabsorbable, high-molecular-weight anionic polymer that has no antimicrobial activity but neutralizes both",
"    <em>",
"     C. difficile",
"    </em>",
"    toxin A and B. It is used alone, since it may bind and neutralize simultaneously administered antibiotics. In phase III trials in adults, cure rates were only about one-half of those of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    , but among responders the relapse rate was lower, suggesting that further study as a follow-up medication is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/58\">",
"     58",
"    </a>",
"    ]. Potential adverse effects include hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Passive immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding that host antitoxin antibodies correlate with clinical outcome has led to development of both active and passive immunization for",
"    <em>",
"     C. difficile",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Active immunization could potentially be used to prevent primary or recurrent",
"    <em>",
"     C. difficile",
"    </em>",
"    infection and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Passive immunotherapy could potentially be given during illness both to treat active",
"    <em>",
"     C. difficile",
"    </em>",
"    infection and prevent relapse. Particularly promising is a combination of human monoclonal toxin A and toxin B antibodies directed at the toxins&rsquo; receptor-binding domains. In a phase II clinical trial in adults, these monoclonal antitoxins, added to standard antimicrobial treatment, had little effect on active disease, but reduced the risk of relapse by 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/63\">",
"     63",
"    </a>",
"    ]. Phase III trials of monoclonal human IgG1 antitoxin A (actoxumab) and antitoxin B (bezlotoxumab) are in progress. Limitations of passive antibody are its relatively short duration and high cost.",
"   </p>",
"   <p>",
"    Intravenous gamma globulin (IVIG), which contains at least low levels of functional antitoxin antibodies, has been anecdotally reported to show benefit. In an uncontrolled trial in five children who had relapsing",
"    <em>",
"     C. difficile",
"    </em>",
"    colitis and low IgG antitoxin A levels, administration of IVIG, 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every three weeks, was followed by resolution of symptoms and clearance of fecal cytotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/64\">",
"     64",
"    </a>",
"    ]. This outcome may have been either a benefit of the treatment or due to the natural history of the disease. A retrospective case-control study found no benefit to treatment with IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/65\">",
"     65",
"    </a>",
"    ]. Pending controlled trials, treatment with IVIG cannot be strongly recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics have limited value in the treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in adults, and there are no data in children. Probiotics are not recommended by American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1\">",
"     1",
"    </a>",
"    ]. The role of probiotics in the treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21015?source=see_link&amp;anchor=H12810765#H12810765\">",
"     \"Clostridium difficile and probiotics\", section on 'Treatment of CDAD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fecal microbiota transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a mouse model, partial reconstitution with mixtures of more than 100 indigenous bacterial strains failed to eliminate",
"    <em>",
"     C. difficile",
"    </em>",
"    ;",
"    <em>",
"     C. difficile",
"    </em>",
"    was eliminated only after reconstitution with the complete intestinal flora from normal mice [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/66\">",
"     66",
"    </a>",
"    ]. This observation provides a basis for clinical treatment with fecal transplant, or bacteriotherapy, a technique in which an aliquot of fecal bacteria obtained from a healthy donor is administered via the intracolonic or intragastric route, both of which are approximately 90 percent effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link&amp;anchor=H2#H2\">",
"     \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two case reports of successful fecal transplantation for",
"    <em>",
"     C. difficile",
"    </em>",
"    colitis in children in whom other forms of treatment repeatedly failed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]; in both cases a parent was the donor. Until there is further experience, we suggest this approach only for similarly difficult circumstances. Fecal microbiota transplantation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link\">",
"     \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multicenter cohort of 4895 children hospitalized with",
"    <em>",
"     C. difficile",
"    </em>",
"    -associated diarrhea during 2001-2006, 1.2 percent had colectomies and 3.8 percent died [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case series and case-control studies, the relapse rate among children hospitalized with",
"    <em>",
"     C. difficile",
"    </em>",
"    disease ranged from 7 to 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/9,43,69\">",
"     9,43,69",
"    </a>",
"    ]. Higher rates of relapse were reported in more severely ill patients and children with underlying inflammatory bowel disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid diagnosis and treatment of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in hospitalized patients minimize the amount of",
"    <em>",
"     C. difficile",
"    </em>",
"    that is shed into the environment. Additional measures for the prevention of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection include antibiotic stewardship, avoidance of proton pump inhibitors, and infection control practices, including rigorous hand hygiene, contact precautions, properly handling contaminated waste, and disinfecting fomites [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,5,44,70\">",
"     1,5,44,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antibiotic stewardship",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic stewardship means avoiding unnecessary antibiotic use and using the narrowest antibiotic spectrum possible in clinical practice, as well as using correct doses for the shortest adequate duration. Early switch from intravenous to oral therapy facilitates early discharge from the hospital. Antibiotic stewardship programs have been effective in reducing the rates of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\", section on 'Antibiotic restriction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27380732\">",
"    <span class=\"h2\">",
"     Avoidance of proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible the use of proton pump inhibitors should be discontinued or replaced with histamine-2 blockers in hospitals or other settings where it is desirable to minimize acquisition and transmission of",
"    <em>",
"     C. difficile",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/71\">",
"     71",
"    </a>",
"    ]. This is particularly true for patients with increased susceptibility such as those receiving antimicrobial treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed practice recommendation for prevention of",
"    <em>",
"     C. difficile",
"    </em>",
"    infection in acute-care hospital settings from the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America is available [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/72\">",
"     72",
"    </a>",
"    ]. The recommendations are summarized briefly here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Hand hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hand-washing with soap and water is preferred to alcohol-based hand gels when",
"    <em>",
"     C. difficile",
"    </em>",
"    exposure is likely (eg, after entering areas occupied by patients with known or recent",
"    <em>",
"     C. difficile",
"    </em>",
"    infection) because alcohol-based gels are not sporicidal. The mechanical action of hand washing with soap and water is required to eradicate",
"    <em>",
"     C. difficile",
"    </em>",
"    spores from contaminated hands. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\", section on 'Hand hygiene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Contact precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surfaces that are frequently touched in patient bathrooms, such as light switches and door handles, have been directly implicated in",
"    <em>",
"     C. difficile",
"    </em>",
"    transmission. We recommend single-patient rooms and exclusion from common areas whenever possible. Dedicated equipment, including electronic thermometers and stethoscopes should be provided whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Gloves should be worn when entering the room and an impervious gown should be worn if there is an expectation of contact with body substances or contaminated surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics recommends contact precautions in addition to standard precautions throughout the duration of illness for children hospitalized with infectious diarrhea, including",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of infection control\", section on 'Standard precautions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles of infection control\", section on 'Isolation precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Disinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental contamination with",
"    <em>",
"     C. difficile",
"    </em>",
"    is caused by persistence of spores that are highly resistant to most hospital disinfectants and can survive for many weeks or months on dry surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/8,77,78\">",
"     8,77,78",
"    </a>",
"    ]. Hospital rooms and bathrooms of patients with",
"    <em>",
"     C. difficile",
"    </em>",
"    infection should be cleaned with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"     sodium hypochlorite",
"    </a>",
"    (household bleach) diluted 1:10 with water [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,77\">",
"     1,77",
"    </a>",
"    ]. Ultraviolet light is effective in reducing",
"    <em>",
"     C. difficile",
"    </em>",
"    spores and may ultimately play a role as well [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/79\">",
"     79",
"    </a>",
"    ]. Environmental disinfection is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\", section on 'Hospital environmental cleaning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Child care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with diarrhea, regardless of cause, should be excluded from child care settings for the duration of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/3\">",
"     3",
"    </a>",
"    ]. Infection control measures, such as sanitizing diaper changing surfaces and dressing with clothes over diapers, should be reinforced [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1089680743\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data regarding the effectiveness of probiotics in the prevention of",
"    <em>",
"     C. difficile",
"    </em>",
"    in children. Probiotics are not recommended by American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The role of probiotics in the prevention of",
"    <em>",
"     C. difficile",
"    </em>",
"    disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21015?source=see_link&amp;anchor=H5#H5\">",
"     \"Clostridium difficile and probiotics\", section on 'Prevention of CDAD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27821361\">",
"    <span class=\"h2\">",
"     Replacement strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontoxigenic",
"    <em>",
"     C. difficile",
"    </em>",
"    strains can colonize and exclude toxigenic strains. Prophylaxis with nontoxigenic strains is in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding that antitoxin antibodies correlate with clinical outcome provides a basis for development of both passive and active immunization to prevent primary or recurrent",
"    <em>",
"     C. difficile",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Passive immunization is discussed above (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Passive immunotherapy'",
"    </a>",
"    above). Active immunization with vaccines against toxins A and B and bacterial surface antigens are under development [",
"    <a class=\"abstract\" href=\"UTD.htm?14/5/14426/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention and control of Clostridium difficile in hospital and institutional settings\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following treatment guidelines are compatible with recommendations of the American Academy of Pediatrics Committee on Infectious Diseases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No treatment is indicated for children who are asymptomatic carriers of",
"      <em>",
"       Clostridium difficile",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asymptomatic carrier'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care for children with",
"      <em>",
"       C. difficile",
"      </em>",
"      diarrhea involves maintenance of hydration and nutritional status. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial step in the treatment of",
"      <em>",
"       C. difficile",
"      </em>",
"      infection is discontinuation of inducing antibiotics. If antibiotics cannot be discontinued, ongoing antimicrobial therapy should be narrowed and shortened as much as possible. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Discontinuation of inducing antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimicrobial treatment for laboratory-confirmed",
"      <em>",
"       C. difficile",
"      </em>",
"      diarrhea is indicated for children with moderate to severe disease (ie, fever, profuse diarrhea, abdominal tenderness, abdominal distension, leukocytosis, volume depletion, electrolyte imbalance, pseudomembranous colitis), underlying gastrointestinal tract disease or immune compromise, or for children with persistent diarrhea after the inducing antibiotics have been discontinued. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      as the drug of choice for children and adolescents with moderate",
"      <em>",
"       C. difficile",
"      </em>",
"      disease (ie, fever, profuse diarrhea, abdominal tenderness, leukocytosis, but with no abdominal distension, clinical sepsis, hypotension, volume depletion, electrolyte imbalance, or pseudomembranous colitis), or underlying gastrointestinal tract disease or immune compromise (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dose of metronidazole is 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by mouth in four divided doses for at least 10 days; maximum 2 g per day. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      for children and adolescents with severe",
"      <em>",
"       C. difficile",
"      </em>",
"      disease (ie, clinical sepsis, hypotension, volume depletion, abdominal distention, peritonitis, electrolyte imbalance, pseudomembranous colitis, underlying intestinal tract disease, or immune compromise) and those who do not respond to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       metronidazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dose of vancomycin is 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by mouth in four divided doses (maximum 500 mg per day) for 10 days.",
"      <br/>",
"      <br/>",
"      Teicoplanin is an alternative for severe disease in countries where it is available. The optimal dose of teicoplanin for",
"      <em>",
"       C. difficile",
"      </em>",
"      has not been established. In adults, oral regimens of 50 mg four times daily for three days followed by 100 mg twice daily for four days, and 400 mg twice daily for 10 days have compared favorably with other regimens; there are no data in children. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The response to treatment is monitored clinically; follow-up stool studies generally are not recommended. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients remain vulnerable to recurrent infection for up to 10 weeks following treatment for",
"      <em>",
"       C. difficile",
"      </em>",
"      infection. Antimicrobial treatment and hospitalization should be avoided if possible during that period of vulnerability. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal management for the treatment of",
"      <em>",
"       C. difficile",
"      </em>",
"      relapse is not established. The first relapse should be retreated with the same antibiotic that was used initially. Subsequent relapses may be treated with oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      in tapering or pulsed dosing, or with alternative antibiotics. (See",
"      <a class=\"local\" href=\"#H36637750\">",
"       'Treatment of recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methods to prevent",
"      <em>",
"       C. difficile",
"      </em>",
"      infection include antibiotic stewardship, avoidance of proton-pump inhibitors in at-risk patients, and implementation of infection control measures, including contact precautions and hand hygiene with soap and water, since alcohol-based agents do not kill",
"      <em>",
"       C. difficile",
"      </em>",
"      spores. Hospital rooms and bathrooms of patients with",
"      <em>",
"       C. difficile",
"      </em>",
"      infection should be cleaned with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"       sodium hypochlorite",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Follow-up should include a stated plan to avoid antibiotics for ten weeks if at all possible. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Discontinuation of inducing antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author gratefully acknowledges the assistance of Caryn Scoville, librarian III and Information Services librarian, University of Missouri Libraries.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/1\">",
"      Schutze GE, Willoughby RE, Committee on Infectious Diseases, American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics 2013; 131:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/2\">",
"      Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Clostridium difficile. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LJ.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/4\">",
"      Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/5\">",
"      Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340:c1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/6\">",
"      Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974; 81:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/7\">",
"      Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/8\">",
"      Wilcox MH, Fawley WN, Wigglesworth N, et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003; 54:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/9\">",
"      Morinville V, McDonald J. Clostridium difficile-associated diarrhea in 200 Canadian children. Can J Gastroenterol 2005; 19:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/10\">",
"      Gogate A, De A, Nanivadekar R, et al. Diagnostic role of stool culture &amp; toxin detection in antibiotic associated diarrhoea due to Clostridium difficile in children. Indian J Med Res 2005; 122:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/11\">",
"      Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; :CD004610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/12\">",
"      Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/13\">",
"      Dubberke ER, Yan Y, Reske KA, et al. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol 2011; 32:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/14\">",
"      Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/15\">",
"      Drekonja DM, Amundson WH, Decarolis DD, et al. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med 2011; 124:1081.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/16\">",
"      Church JM, Fazio VW. A role for colonic stasis in the pathogenesis of disease related to Clostridium difficile. Dis Colon Rectum 1986; 29:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/17\">",
"      Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/18\">",
"      Youssef DA, Ranasinghe T, Grant WB, Peiris AN. Vitamin D's potential to reduce the risk of hospital-acquired infections. Dermatoendocrinol 2012; 4:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/19\">",
"      Vasa CV, Glatt AE. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gastroenterol 2003; 98:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/20\">",
"      Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011; 155:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/21\">",
"      de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/22\">",
"      Wenisch C, Parschalk B, Hasenh&uuml;ndl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813.",
"     </a>",
"    </li>",
"    <li>",
"     Dificid (Fidaxomicin) prescribing information www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdf (Accessed on February 06, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/24\">",
"      Sullivan KM, Spooner LM. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann Pharmacother 2010; 44:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/25\">",
"      Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 2010; 11:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/26\">",
"      Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/27\">",
"      Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/28\">",
"      Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 Suppl 2:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/29\">",
"      Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/30\">",
"      Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/31\">",
"      Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008; 52:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/32\">",
"      Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008; 359:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/33\">",
"      Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/34\">",
"      Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/35\">",
"      Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/36\">",
"      Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group. Scand J Infect Dis 1994; 26:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/37\">",
"      Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; :CD007022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/38\">",
"      Apisarnthanarak A, Khoury H, Reinus WR, et al. Severe Clostridium difficile colitis: the role of intracolonic vancomycin? Am J Med 2002; 112:328.",
"     </a>",
"    </li>",
"    <li>",
"     Singh N, Hyun DY. Clostridium difficile. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/40\">",
"      Wenisch JM, Schmid D, Kuo HW, et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012; 56:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/41\">",
"      Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6 Suppl 1:S235.",
"     </a>",
"    </li>",
"    <li>",
"     Ferry G, Versalovic J. Antibiotic-associated colitis. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/43\">",
"      Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe clostridium difficile infection in children. Pediatr Infect Dis J 2012; 31:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/44\">",
"      Cohen MB. Clostridium difficile infections: emerging epidemiology and new treatments. J Pediatr Gastroenterol Nutr 2009; 48 Suppl 2:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/45\">",
"      McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/46\">",
"      Johnson S, Gerding DN. Fidaxomicin \"chaser\" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis 2013; 56:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/47\">",
"      Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996; 40:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/48\">",
"      Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/49\">",
"      Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/50\">",
"      Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/51\">",
"      Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005; 3:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/52\">",
"      Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013; 37:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/53\">",
"      Patrick Basu P, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 2010; 3:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/54\">",
"      Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/55\">",
"      Miller MA, Blanchette R, Spigaglia P, et al. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol 2011; 49:4319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/56\">",
"      Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/57\">",
"      Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980; 141:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/58\">",
"      Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents 2009; 33:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/59\">",
"      Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/60\">",
"      Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/61\">",
"      Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/62\">",
"      Warny M, Vaerman JP, Avesani V, Delm&eacute;e M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/63\">",
"      Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/64\">",
"      Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/65\">",
"      Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. Am J Infect Control 2007; 35:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/66\">",
"      Wilson KH, Freter R. Interaction of Clostridium difficile and Escherichia coli with microfloras in continuous-flow cultures and gnotobiotic mice. Infect Immun 1986; 54:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/67\">",
"      Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010; 126:e239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/68\">",
"      Kahn SA, Young S, Rubin DT. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol 2012; 107:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/69\">",
"      Kelsen JR, Kim J, Latta D, et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/70\">",
"      Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol 2010; 105:2327.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs) www.fda.gov/Drugs/DrugSafety/ucm290510.htm (Accessed on March 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/72\">",
"      Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/73\">",
"      Brooks SE, Veal RO, Kramer M, et al. Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol 1992; 13:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/74\">",
"      Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/75\">",
"      Duncan IB, Batchelor C. Assessment of the effectiveness of body substance precautions as the infection control system of a large teaching hospital. Am J Infect Control 1993; 21:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/76\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012; 61:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/77\">",
"      Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/78\">",
"      Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988; 127:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/79\">",
"      Rutala WA, Weber DJ. Are room decontamination units needed to prevent transmission of environmental pathogens? Infect Control Hosp Epidemiol 2011; 32:743.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Children in out-of-home child care. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, et al.  (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/81\">",
"      Villano SA, Seiberling M, Tatarowicz W, et al. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 2012; 56:5224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/5/14426/abstract/82\">",
"      Rebeaud F, Bachmann MF. Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines 2012; 11:469.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6050 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.102.30.19-B30E4C65A7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14426=[""].join("\n");
var outline_f14_5_14426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asymptomatic carrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Discontinuation of inducing antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H100909150\">",
"      Moderate or persistent mild disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H100909159\">",
"      Severe disease or risk for severe disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H80878967\">",
"      - Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36637750\">",
"      - Treatment of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73645980\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Toxin binders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Passive immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Probiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fecal microbiota transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antibiotic stewardship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27380732\">",
"      Avoidance of proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Hand hygiene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Contact precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Disinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Child care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1089680743\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27821361\">",
"      Replacement strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Immunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21015?source=related_link\">",
"      Clostridium difficile and probiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=related_link\">",
"      Clostridium difficile infection in children: Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=related_link\">",
"      Clostridium difficile infection in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=related_link\">",
"      Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=related_link\">",
"      Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=related_link\">",
"      Prevention and control of Clostridium difficile in hospital and institutional settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_5_14427="Survival MDS by IPSS and age";
var content_f14_5_14427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Median survival (in years) in myelodysplastic syndrome according to International Prognostic Scoring System (IPSS) and age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        IPSS risk group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age &le;60",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age &gt;60",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age &gt;70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        11.8",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermediate-1",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermediate-2",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Greenberg, P, Cox, C, Le Beau, MM, et al, Blood 1997; 89:2079.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14427=[""].join("\n");
var outline_f14_5_14427=null;
var title_f14_5_14428="Undifferentiated overlap synd";
var content_f14_5_14428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Undifferentiated rheumatic diseases and overlap syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Synonyms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Mixed connective tissue disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lupus-scleroderma-polymyositis-rheumatoid arthritis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Undifferentiated systemic rheumatic disease",
"       </td>",
"       <td>",
"        (Early) undifferentiated connective tissue, collagen vascular, or autoimmune disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Nonclassic systemic lupus erythematosus",
"       </td>",
"       <td>",
"        Lupus-like, lupus variant, or near, borderline, latent, incipient, incomplete, possible, or probable lupus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Overlap syndromes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatoid arthritis-lupus",
"       </td>",
"       <td>",
"        Rhupus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scleroderma-polymyositis/dermatomyositis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scleroderma-lupus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scleroderma-rheumatoid arthritis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polymyositis overlaps",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Juvenile idiopathic arthritis-lupus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sj&ouml;gren's syndrome overlaps",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Other",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Undifferentiated polyarthritis syndrome",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Undifferentiated spondyloarthritis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14428=[""].join("\n");
var outline_f14_5_14428=null;
var title_f14_5_14429="Med mgmt gastroparesis";
var content_f14_5_14429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical management of gastroparesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism(s) of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse reactions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Availability in US",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Prokinetic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metoclopramide",
"       </td>",
"       <td>",
"        Dopamine antagonist; promotes gastric emptying by sensitizing tissues to the action of acetylcholine",
"       </td>",
"       <td>",
"        5 to 10 mg IV every&nbsp;six hours or 5 to 10 mg&nbsp;orally before meals and at night (increase to 20 mg if no improvement)",
"       </td>",
"       <td>",
"        Drowsiness, restlessness, acute dystonic reactions, arrhythmia (rare), galactorrhea, gynecomastia; long-standing metoclopramide therapy, over three months has a risk of irreversible tardive dyskinesia, in 1 to 10 percent",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin",
"       </td>",
"       <td>",
"        Motilin agonist; induces gastric peristalsis",
"       </td>",
"       <td>",
"        150 to 250 mg&nbsp;orally&nbsp;three times daily or 100 mg IV&nbsp;three times daily",
"       </td>",
"       <td>",
"        Arrhythmias (rare), headache, nausea, vomiting, diarrhea, cholestasis; tachyphylaxis is common; rarely effective beyond one month",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Domperidone",
"       </td>",
"       <td>",
"        Dopamine antagonist similar to metoclopramide but does not cross the blood brain barrier",
"       </td>",
"       <td>",
"        10 to 20 mg three times daily before meals and at night",
"       </td>",
"       <td>",
"        Arrhythmia, galactorrhea, gynecomastia",
"       </td>",
"       <td>",
"        Available only through an IND, limited-access program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tegaserod",
"       </td>",
"       <td>",
"        Serotonin 5-HT",
"        <sub>",
"         4",
"        </sub>",
"        receptor agonist; increases the peristaltic reflex predominantly in small bowel",
"       </td>",
"       <td>",
"        6 mg&nbsp;orally 30 mins before meals&nbsp;three times daily",
"       </td>",
"       <td>",
"        Headache, abdominal pain, nausea, diarrhea; rare: angina, ischemic colitis, increased transaminase levels",
"       </td>",
"       <td>",
"        No longer approved in the US",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cisapride",
"       </td>",
"       <td>",
"        Increases acetylcholine by stimulating serotonin receptors and stimulates gastrointestinal motility",
"       </td>",
"       <td>",
"        10 mg&nbsp;orally four&nbsp;times daily before meals",
"       </td>",
"       <td>",
"        Serious: ventricular arrhythmia and prolonged QT interval; rash, abdominal pain, diarrhea, headache",
"       </td>",
"       <td>",
"        Available only through an IND, limited-access program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Antiemetic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ondansetron",
"       </td>",
"       <td>",
"        Serotonin 5-HT",
"        <sub>",
"         3",
"        </sub>",
"        receptor antagonist; acts peripherally by selectively binding to 5-HT",
"        <sub>",
"         3",
"        </sub>",
"        receptors on the vagus nerve and centrally in the area postrema of the chemoreceptor trigger zone",
"       </td>",
"       <td>",
"        8 mg&nbsp;orally or IV every&nbsp;eight hours",
"       </td>",
"       <td>",
"        Constipation, xerostomia, fatigue, dizziness; rare: arrhythmia, increased transaminase levels",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prochlorperazine",
"       </td>",
"       <td>",
"        Acts centrally by inhibiting dopamine receptors in the medullary chemoreceptor trigger zone and peripherally by blocking the vagus nerve",
"       </td>",
"       <td>",
"        5 to 10 mg orally or IV every&nbsp;six hours",
"       </td>",
"       <td>",
"        Hypotension, galactorrhea, gynecomastia, weight gain, drowsiness, dystonic reaction; rare: neuroleptic malignant syndrome, prolonged QT interval",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Tricyclic antidepressants, such as nortriptyline (10 to 75 mg every night), or investigational drugs, such as mirtazapine and dronabinol (Marinol), can be considered for refractory malignant gastroparesis.",
"    <div class=\"footnotes\">",
"     US: United States; IV: intravenous; IND: investigational new drug; 5-HT",
"     <sub>",
"      4",
"     </sub>",
"     : 5-hydroxytryptamine-4; FDA: US Food and Drug Administration; 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     : 5-hydroxytryptamine-3.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Donthireddy K, Ailawadhi S, Nasser E, et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 2007; 5:355. Illustrations used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14429=[""].join("\n");
var outline_f14_5_14429=null;
var title_f14_5_14430="Evaluation bronchiectasis 1";
var content_f14_5_14430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56821%7EPULM%2F69598%7EPULM%2F81561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56821%7EPULM%2F69598%7EPULM%2F81561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of bronchiectasis-1",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific examples/features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Acquired bronchial obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Foreign-body aspiration",
"       </td>",
"       <td>",
"        Peanut; chicken bone; tooth; grass inflorescence, etc",
"       </td>",
"       <td>",
"        Chest imaging; fiberoptic bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tumors",
"       </td>",
"       <td>",
"        Laryngeal papillomatosis; airway adenoma; endobronchial teratoma",
"       </td>",
"       <td>",
"        Chest imaging; fiberoptic bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hilar adenopathy",
"       </td>",
"       <td>",
"        Tuberculosis; histoplasmosis; sarcoidosis",
"       </td>",
"       <td>",
"        PPD; chest imaging; fiberoptic bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        COPD",
"       </td>",
"       <td>",
"        Chronic bronchitis",
"       </td>",
"       <td>",
"        Pulmonary function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatic&nbsp;disease",
"       </td>",
"       <td>",
"        Relapsing polychondritis (RP); tracheobronchial amyloidosis",
"       </td>",
"       <td>",
"        Clinical syndrome of RP/cartilage biopsy; biopsy for amyloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucoid impaction",
"       </td>",
"       <td>",
"        Allergic bronchopulmonary aspergillosis; bronchocentric granulomatosis (BG); postoperative mucoid impaction",
"       </td>",
"       <td>",
"        Total and aspergillus specific IgE; specific aspergillus IgG; Aspergillus skin test; chest imaging; biopsy for BG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Congenital anatomic defects that may cause bronchial obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tracheobronchial",
"       </td>",
"       <td>",
"        Bronchomalacia; bronchial cyst; cartilage deficiency (Williams-Campbell syndrome); tracheobronchomegaly (Mounier-Kuhn syndrome); ectopic bronchus; tracheoesophageal fistula",
"       </td>",
"       <td>",
"        Chest CT imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vascular",
"       </td>",
"       <td>",
"        Pulmonary (intralobar) sequestration; pulmonary artery aneurysm",
"       </td>",
"       <td>",
"        Chest CT imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphatic",
"       </td>",
"       <td>",
"        Yellow-nail syndrome",
"       </td>",
"       <td>",
"        History of dystrophic, slow growing nails",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     COPD: chronic obstructive pulmonary disease; RP: relapsing polychondritis; BG: bronchocentric granulomatosis; CT: computerized tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of bronchiectasis-2",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific examples/features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Immunodeficiency states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IgG deficiency",
"       </td>",
"       <td>",
"        Congenital (Bruton's type) agammaglobulinemia; selective deficiency of subclasses (IgG2, IgG4); acquired immune globulin deficiency; common variable hypogammaglobulinemia; Nezelof's syndrome; \"bare lymphocyte\" syndrome",
"       </td>",
"       <td>",
"        Quantitative immunoglobulin levels; immunoglobulin subclass levels; impaired response to immunization with pneumococcal vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IgA deficiency",
"       </td>",
"       <td>",
"        Selective IgA deficiency &plusmn; ataxia-telegiectasia syndrome",
"       </td>",
"       <td>",
"        Quantitative immunoglobulin levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukocyte dysfunction",
"       </td>",
"       <td>",
"        Chronic granulomatous disease (NADPH oxidase dysfunction)",
"       </td>",
"       <td>",
"        Dihydrorhodamine 123 (DHR) oxidation test; nitroblue tetrazolium test; genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other rare humoral immunodeficiencies (CXCR4 mutation, CD40 deficiency, CD40 ligand deficiency, and others)",
"       </td>",
"       <td>",
"        WHIM; Hypergammaglobulinemia M",
"       </td>",
"       <td>",
"        Neutrophil count; quantitative immunoglobulin levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Abnormal secretion clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciliary defects of airway mucosa",
"       </td>",
"       <td>",
"        Kartagener's syndrome; ciliary dyskinesis",
"       </td>",
"       <td>",
"        Chest image showing situs inversus; bronchial biopsy; ciliary motility studies; electron microscopy of sperm or respiratory mucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cystic fibrosis (mucoviscidosis)",
"       </td>",
"       <td>",
"        Typical early childhood syndrome; later presentation with predominantly sinopulmonary symptoms",
"       </td>",
"       <td>",
"        Sweat chloride; genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Young's syndrome",
"       </td>",
"       <td>",
"        Obstructive azoospermia with sinopulmonary infections",
"       </td>",
"       <td>",
"        Sperm count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Miscellaneous disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha-1 antitrypsin deficiency",
"       </td>",
"       <td>",
"        Absent or abnormal antitrypsin synthesis and function",
"       </td>",
"       <td>",
"        Alpha-1 antitrypsin level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent aspiration pneumonia",
"       </td>",
"       <td>",
"        Alcoholism; neurologic disorders; lipoid pneumonia",
"       </td>",
"       <td>",
"        History; chest imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatic&nbsp;disease",
"       </td>",
"       <td>",
"        Associated with rheumatoid arthritis and Sjogren's syndrome",
"       </td>",
"       <td>",
"        Rheumatoid factor; antiSSA/antiSSB; salivary gland MRI or biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory bowel disease",
"       </td>",
"       <td>",
"        Crohn's disease; ulcerative colitis",
"       </td>",
"       <td>",
"        History; lower gastrointestinal endoscopy; imaging studies; colonic biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inhalation of toxic fumes and dusts",
"       </td>",
"       <td>",
"        Ammonia; nitrogen dioxide, or other irritant gases; smoke; talc; silicates",
"       </td>",
"       <td>",
"        Exposure history; chest imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic rejection following organ transplantation",
"       </td>",
"       <td>",
"        Bone marrow, lung and heart lung transplantation; associated with obliterative bronchiolitis",
"       </td>",
"       <td>",
"        History; PFT; chest CT imaging with inspiratory and expiratory views",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of bronchiectasis-3",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Specific examples",
"      </td>",
"      <td class=\"subtitle1\">",
"       Diagnostic tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Childhood infections",
"      </td>",
"      <td>",
"       Pertussis; measles",
"      </td>",
"      <td>",
"       History of infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacterial infections",
"      </td>",
"      <td>",
"       Infections due to Staphylococcus aureus, Klebsiella, Pseudomonas aeruginosa",
"      </td>",
"      <td>",
"       History of infection; sputum culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Viral infections",
"      </td>",
"      <td>",
"       Infections due to adenovirus (particularly types 7 and 21), influenza, herpes simplex",
"      </td>",
"      <td>",
"       History/serologic evidence of infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other infections",
"      </td>",
"      <td>",
"       Fungal (histoplasmosis); Mycobacterium tuberculosis, nontuberculous mycobacteria; possibly mycoplasma",
"      </td>",
"      <td>",
"       Fungal culture; AFB smear and mycobacterial culture",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AFB: acid-fast bacilli.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14430=[""].join("\n");
var outline_f14_5_14430=null;
var title_f14_5_14431="Calyceal brush in medullary sponge kidney";
var content_f14_5_14431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calyceal brush in medullary sponge kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 239px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAO8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCPx74x8UWnjjxDb2viHUYbWG9kSOGOXGxR0AHpWNB458XlCW8Sang8Z83pTfiKA/xG8RqqkEahJyByOlYsSkLtVduTyT6UAdRb+NfFrMwXxDqLsvYy1ctvGHil1dm8QakQqZ4m7/1rnImIQDgjHA75HeriA/MyjPGT7H0oA6GPxd4lYKP+Eg1D7vJ82r0HifxI8QkbXb/OenmY4rnI8FsoQBjJJxV2DJkQEuQeevSgDe/4SnxAoRjrN/zxgyGraeJddwM6zfHnLfvOR7VjQR5cbmbap4960IUwpDKFJ5J9qANRPEmtOoxqt4c9CHqVNe1plw2r3m5ugElZoj+U7AcNj2zV7TbNHJ8xuewI60AaNjqHiC7ZUj1W7IHJPmcmu00WHUpgnmajctzggvzWdo2nxIig5+YYzjp9K7HSYkVOB06HHWgC7bxGGIK0juR1Zzk1LQQCMEZFFABRRRQAUUjsqLliAPekjkSRcxurD1U5oAdWJ4nuJLa03xTPG2P4TituuZ8atm2RAR0J5oA4V9b1UFwmqXJIzkF+1NTW9T3MTqt35YORmTk1nXWA5IIDYx9arbmWRiyqSce/5UAdLb6xqTKzNqN3luQC/StOy1S+kYf6bO2ePmbGfwrm7KQsisjDLHrWza5DBSAVPGCMH65oA6CO4vXQZvJNjEAnOCB/jWnC10W/1ztnp83ArItcY27VRQOSed30rTtnTdv34AAIAHU0AacZkVN0jnLDA5/zzVtWGFBPzEVVR1BTeBzkcn+lSKpAySz7TlR0P0oAsUU0MD057fSnUAfHHxAXb8RvE2W2k6hIQM9ayIeN0gIA9T1rT+Ikn/FxvE+35SL+TOe/SsaO4UKijjPG3HfNAGpGq7kEu4OPmGB96pwSFdkX94ODlsAfWqSyom0FPlbgnPI/wqxEFZRySMA+/wBKALkClmUSJtOMYU559a0rc4c7mVzjkg9qowOW3Y+4p+YAVo2ePl3jCk9B1xQBqW7qyx7UIPXBrXt4OcvyrjPzVV06LygzPyp4FbVg8nkhTIHGTnAoAVYNyxgheOi+ldBaWSfK0gU4G7aP51mQJH5igja2ckHpW1aYilTHPOCO+KANiziUlk/5ZN1XPaul004iGfoK5uEIZgQAEB4x1JrorCThSqFg/BK9F+tAF+iiigAooooAhu7dLqBopMgMMZFZ+h6P/ZQcLOzqTwvYVrUUAFcN44vF3smSCvGB1+v0rt5XCRsxOABmvKfGd4JLmQqcge33qAOakky7fL97gj09/pUO7DsJOCeAc8ioJyZNpBIYDLL2x6U6EHzFXAYdd1AG5pxZdmwE55ZgOGro4Cn2YMx+U8//AFq5+zJwA5UAdPQ+1blsysu1SCCMsMdPpQBo27sJVBf5cbt2P0rRgfYwZ1yysCQf4axxIYiqoTtH3c8/5FXIrpd6MMMcAfU0Ab0E0rjcqE8nqOlT7yPm5bkAc1kwzNtbcxCDnGemPT1qVLoggFjlmznOc+gNAGskxE21lC+rZ/QVdrEtpnW47bf4ia2x0oA+I/iW5PxM8ThSQBqUoII+lZUMp7jAzjOa0fiY3l/E3xTJkgjUZcDqCeKxIpTx1VifTgUAaas2V3EkHnnqRWhburZYEe2Tg1mW5URbmclhwK0LcqVJQEY46fe9qANWJm2/KMnv6mtbS5grDdnd057Vi2zh1ABK56qetbmnRfvOMEHFAHRWJZYzuye2T3rWt3GxV2j3XNZERVVAYEAcjbV1HT5MO232FAGzbyY+Y4BBxjrj3q1M1zOkQ065jtHDZd5E37h3GOxrKtiigNgoDk4J61ftJQwyvyqDgDvQB0Vo4Z9q4z3Oe4rsdJfdFgADgZxXD2UqY+8AScfL/Wu00STdDhApQdweaANSiiigAooooAKKKKAM/XpjBpsjAZJGBXjOtztLN8+CBXrniGcfZ2jHIHUY6/SvO9VtVeY7QoPXJGPwoA5FUlUcYPP3s8VNEpysm7I/LNaNzaqgdsYdu2aqNFGsnHJHABoA1NPwAOVYN1zxWhDM6gqD8pzhsYrIiYRhcHLemOlTNK2ADlWPVs5AoA2rZkd2IkJbGBnv61dtVOFy+xSwBHXHvisWzLoAq7nGcjPrWnHKrtjB80/kKANUSooYbshSdtPBBkjSJ8huWYdPpVO1+dcsm4Lkf/XxVyPDJlXCleA3QN7UAaVnF5rjd/e7f1rolGFAHauWtbl1jHOFOCOf511KfcXPpQB8MfFCT/i5/itf+ojKACPpWLHhVBkPU8c/zrU+Kblfil4r5JI1KXBHbpWJbSZGMKW65NAGlExIRcgKucD1NakBVUCxgnJ5Oax4XCqPnXBOdp6Gr1vIvJVgF6g/0oA3opD8oRG6YzmtayuSAFQoMHkY6f4muYjdgxAbAx0z0q/aXDD92oG3Gfm7e9AHZW10FCqxO8dSpzmrqzssuUKleBjpXKWM/wC7jxuDscnHatLzucOAxB++DkUAdTHehmKMVC/wrU9vcky7QAMDJx3rmYpd8uGJwpzx3q5DMUIAb5j3PT6UAdnY3IZV5ySeVH8P+Nej+Fxm1yVANeX+Go/tEigKVAPSvU9HXyEwOTjBwaANiiiigAoopGYL1PPYetAC1DdTCGF2JGQO9E8oRRkHn0Nc1r9+UVgD948Z7UAVby4FxJIz5ZQPl+tYtwVBeQKoyOfrUE17ICzszc8YHTNZuoahujVh8rjjHY0AMuJFYDOT6Af1rLkchskgk9faiW5LuVLD69CfYVXLBsg8MW+tAFkMNiEnJXrg4NSwurkNuKqM8k9T71nO6+YQmWYccHFWINxc7SpPG0Djn3oA2reUbUVT83bPYVoCZjJtlIEbYHHT2rnklBlARsuvbsTWqkoYqHUPjkHt7igDctScEqc8HJHFWftARsnGFweBhV/D1rMgnYRFRtBK9M9RVlHOfmIZm/vcigDY0+MSSKq7fmOSCecV2CjCgegxXK+G7YySBn5YYJbuPaur70AfBvxTZB8U/FmEB/4mcuc9+nWsW3dSMtkHPpxWt8VTj4qeLccgalKTn8KwImwwDDPv60AaiPkrgDPbjir0D7QSWGMjqKyYXxgd88ZHT61oxAMjFcMufpn3oA0IT8gGQpzkAnk1dRshShwcc/7NUYFVFIxuUGriEEBcDION2euelAGnauFEZc8jhSO1aNvPlxgAxseQOhNYcfyO+SdvQ57n2q9alwqqozyF46AUAbTuVmRFBXBwMVq2ERunRlyWDDJUdao6To1xdyKHB653DpXpHh/QhDGGC7JTjBHcUAavh22FtHv5UsecjmurtZVidSxAA/u9TWJYQtDcFyQR2U9z61oRx+VJI+cu5zk9FHtQBtQ3y52v+Jq8rBlDL0Nco0qheXBI6H1q7pmqxn90XVecDPFAG/UbkB1yPmPeoHukVWIIZB6Hmql3eL5YYY3EdO6/SgCO/uCG3Lnd0yK4vxNdJ9pC27MzDkt7+1bWoXB5KsCSOcntXDa/OCdsjkL0yvUfSgCF9QbcdxJJ4ORVKabcx3EqhPIqIOzjls9gx61FdsQcR/Lxz7UALcMhUYHKHqRz+FVlkUcncD/F71RkkJKKfmKnkGpBMpIO5ic9B2FAF1nUIoJwM5x0yKkkmDIzbCARuJ9hVQylwF+VjngEcinrgHOcnON2elAFxbiJsNb4KgDJPUitSC5RZE3piPqFz7dc1z2nyIy/OdqPkqo4xWiSquI9g9Bg8UAbtteRAtgs5T5iCOCtXorgCVAJWw3Kqw7GsG1tzOCdwVfuqTwpb0z3rpNGhjYxCXa2TiIkYx+FAHbeF7dY7FWCY5zknmtv+LvVPSWJsoQw2sB90jGBVvd+8xx0zQB8E/FYkfFbxdgZX+0pc57dKw0ChCozmtz4tE/8LS8WhcEjU5Tj16Vz9uNoGTgfeOetAF62Y7B1GOSW71oW4JdWbAGeMd6o2siEk8HjAz6VoRDbKjAZ3DP0oAtRs4jx0Gcn1xWjbowZcAE9QfWqCFA5XBJYdBW1o1k9zcJGrEk/y9qALdjYy3MnyITk4zj19q9I8M+DSVj81CWByT2p/hvSrXTrZHmYb87jnnArqbbW7aMbbfO0dzxQBr6XoUECqV2knrt7AenvW9HYDYVZdm3BGKwrPXQ8gDBcHuBwTXUWtwk6eZnPA4NAFKW3EUgyMlhj6VFIskQPIIQYGRzWruSR5CwHmoOR2xWZqJ2xgZJB7jqKAOa1i7MNuTs+bOctx+NcgfEZS5LcgKeQaveL7swqvzE4yGGeleeSSmSYssh2KcE+tAHsml+IBceUc7gV69605LoNuAbLHmvKvD96yr8sg69O1d3Fc+ZCrbeQMf8A16AJb4u3UZbHU1yuq52si9CckEdPxro76TEXEmVYcj1rldYfYrAOc4+760AVFJx8w6cDHSqV8/7tmIJAHO7g/hTPPwvL845BPSqFxMsh4kZieMY4FAEBklLOwcFexIyamtyOT1HbPBNUWnAbYykEcbR/FT2lO8Kp3MOFwOlAGtCBsJBxyeeu2pXIQxs7kAnJAHX3qhDI5YLkDIww7H3qZhyw3FlUA5agCyhGRsXcRnC4+9UsV8yTxF7dZcDpnHzD+lQxOz4IGz5cjH9KtRhXdZJBhRwMenrQBr2s0jSZkZRzvVMZVW+n0rqvDkEtzefabls4IxkY/IVyFpGhlV8nJ6Ljt716X4RtnaHfIm1WJIPYUAdbCSY13YzjtQFHnbsfNtx+FOVQqgDoBikDDzdvfGaAPgf4snb8VfFjAtxqcvH5VgQ7fvsSMfqfStv4svn4seLlwSP7TlyfTpWFbhQQWJYdQD2oA0Y3UlfL2hT7Zq9Z5dTvwAOBnrVCzXdKhAynYe/pW1ZQbm2spy/O3saALNvHKylAN2wjp1rtdGKWsYkKHzMYx6Vi2Vi0iRfMBtIOfr/Ot+C3Pz+cSOAuSOaANi2vZriVg0mEIyP8PrWtaSqxIY45BOB3rnrRQiFWOFznBHP1rRtLhvMXBDH34oA6S1JWRkJ25+bAPWu20S+JURFuBjjHWuEtZYyuehzgN3+ldLo29rmNd2JMjb7igDuoW/dMWXa3XIFZmpnEGTndjIHcVp24CxszFiTw2O1c94gu/KtJWbqemOpoA8s8ayEyuCCSOq561xKMGUkAlicZHQCtnxHftPfSgMSi9T/SsgYYIiLhgc4HWgDZ0JGE8acYJ6E8V6PYFUtiwIUKMFQc5rzbQYzJeK7sCvQYFd7aqUiU5bDDPTjFAE1/IygE424+XNcprVz8pckfMMZ961r64LuQjkY4H0rkNeuMkFjgE7eO1AGbPdMzuqkhs81XuZSoDCQk4xsPODUTMuSScAZ6djVJpGPO5SO5Hc0AXkuyWXKgkAjgdKdEx3Fe5PbtVSNsYL5yTwO+fep4sGR2P3h1OOtAG1aruHLHAOM9OasbVYEkEsOqD09ay4phtPmZz0bPQ1oQK+EWPduHIz1b2oA0bWO4uZVhgTL44GcAY75q3Ch8reWBw5Cg9T71RQyRR4jfajr8+Tjn0rQtDFE6IGZ5GyeBkKMdvegDY8P2ouLmMH8s8V61oluIbYE9VGAetefeD4w0rSIm5SMZxznpXp9om0crg0AWKgQAXTcgts5/Op6qxuDqEijsgz780AfBfxZBHxW8X5I2tqco/lWJbJnZlvr/AIVufFcgfFjxcCcZ1KUfyrHtFQ84AGOD70AatioeVQU69MH9a6jR7ff8u7LL0GOv0Nc9ZOVCkBc5y2ev4V0Wl3CpsB3bhxn0oA6O2gKcYUnHc81o+Z8jbwWkb7pHUVnQXI+zqPvMowCT0B71YMhwedwGOfT3FAE4kDMgDt/u+1XIZYjMvHzDkH1rOiAZRIG6nknr+FWLZw8gU9Bz70AdFp77sZcDJ/Kuu8Oh/tkbqzFQeW9K8+julSVViO5icZ9K9R8MRpFbLLPjeQDigDqpp2gh+8VY8/hXl/j7WtkUiRuQTnleea2vE3iaKxhky+WBwoPYV4zquoyX000zSE7csSPT2FAGfeT+fOeWB6sR3qxZ+ZkZU47svUCqsahgrqw3P0BH8617AGd8EFGBwUHT6igDe8OWu52ZOE/hPfNdUiMUUfMccMM4FQaFYNFCjhCO249K2Ht025IJIHGDyfegDm77dGHACh+3piuK1w4BGd5JwMHpXfXkbDcduR6HtXEeJFRI2ZRuxxuxjFAHMyfuWZVbe3fPSq+5D5YYYPUFeMmn3crPGqxrthB6dzVJ38wBn4HoO2KAL8bBHYuTz6fyq5byqrAKjdeM/wBaoQbSwjjDuXHy+n1NaMCxKGRiWlHLtn+VAFuMjzAgwQOee9aNu8kbB0zvHy5zwPpWVbOpY/IAMfMf7tXo+F+6zZO7Of0oAuox4DlWB4XnODWnp6Mp2qVJP6e1YcAO9AFZQvXiur0C3V50BYMh5znk0Aei+D7fbFjYASBzjt613CLtUDqQMZrnvD8QSL5G2yYAAx0FdGOgoADyKo277tTmAPyhAMY96utwpPtWTp0xl1q6yekS8enNAHwn8XHJ+K/i4AdNTm/mKxbSQGIqQcYwPTNa/wAXBn4t+Ls9BqcvHqa5yAsjcgk/XgGgDftZSrxlgMdua37K5O5huUMw/MVycLZxgHJPWtizkjjkOV5UAbs8j2oA6u1nOwZJVh6d617ORnKrgbhyBnt71yKXvKkHtkE9qv218igvuYSMNvX160AdP56iNg6YRRleaQ3ihO+8DtWA+oeXEMyBUPXvVVbwLL80hO84AoA77QfJlmMsmdwAJ7ce9dhqfiq3sdP2LggDAA615C2uGJDGjEInTHb/ABrLub+eeQtLNvVuhFAG74h1ye/mbdISpGc56fhVGCR8bicqOhBrNiWVnOcADk561q2atz8oVGGee4oAu2ylmUDPzcZH8677wxowVVlOXGMEkVi+FdGa9lQxgqVIJA5yK9W0zT1gidQoUdRgUAMhiURDLYUDBxUr2/yqGOQRw1XzYRSp8wPI47c1IlsqwhZTux/nigDkrqBjvCKTkE88YrivEltmLESkrj1716VqFu0i5KE7TwF4rkfENsyH5AvqV7A/40AeP3uYpDuHzKcYqqSobLHGOFFauuWzLdkucAnhqyJMGRtijYCM0AXbaTyrZgCS7H8h7VZR2K4K5AOSw7VXiQKxO4tnB+lX44eiqSFbigCxE8ayBfvAce/tmryMSyjbgHgenvVWO1SPDqrYGOR1b0q5bZQbpVKhn4UHJA96ALsLFZAQ+8Bdq+5ruPBdrtnB8tSxOc9cVxVrGHkUkYAOMDrn1+len+Dbfy+xOc59MUAd3pSshxjIxxt7/WtiqWnQBLdWz15GKu0AQ3MhSMkDOOvsKwtEkRvEN6qvvxCpzjH8RrX1CXZGQG2tjOfaub8Ltv8AFOoPtAzbpj6bjQB8UfF1gPiz4wGPm/tOb+dc1GfkAHCk9TXQ/F0/8Xd8XLu2/wDEzmJPoM1zcTrj93+AoA0YiBtCsWOOn92rMUxH3jyOT/tVmJIcjHCnjdVgNtGCc/7XpQBrwzhUIYgA859T6VZS4DcHlcisaLhcnAHYnqam8xGClAUbPOD+tAG0Z1cHcoaM9AexqASsw2kcdm71SjkJO5Tgg4FWIpQVz97nkelAFkyeYoU8jsO/41PE7Rrg4YE7QKqiUBSVC7/7o9PWpLWVQ/QEeretAGpB5nl7UPCn5j/e9q3vD8ZubmNWUuM8DsprAgKyMfMfAzlSD0Nem/DnRzMyzyD5mPQjrQB6F4ZsDBbIyxpGVH3sfyrrIfLVNwBLgcBazoPLsol81GlK8KE54q7FfIEJdFTf156UAXXCFV80kZ5yPWorhP3RJIUYyV9vaoTfRRb2LBsDis681WOJI3Eitnnaf60AM1IFGLIGY4zwf1rltTVmz5u1R2UDn8as32qhZGOWw5+6DxWNdagQxG7IHPPOKAOJ8R2fmIzKAdpytcrLABMCH6jOB0rudXvI2zuiQsfmDIa5WSKGQhmdolycjGefb2oAjhOUVUA3dxjqKu25EalhgyH16CoBD+73I6Ng8jOCKl8vy4wTH8xPyqe/vQBaikWJ2OWBIyT6GpoZDGhlwT7H+lVQ2PmJBwcFc9RVi2EbKGY5RW7UAbWlgSXMS4ZScZIr13wwoggRG5Q8A/X1ryvw6A93GQD64Ar2HRUxEq/LhumKAOotSUiVQoAU4x6CrZYYPf2qpbL5ca7SzdmJ9KfPK8YyANvGaAM7XJjEjDcFQDGfUY6Vy3gGXzPF2rcnIto/l7feNbesyKI5cfvNxIOTjHvXL/DOQN401lAelrHn/vtqAPj/AOMeP+FueLien9pzfzrmIXJO0HBJ6j0rqfjGp/4W54uyVUHU5uT25rkoZSMkEbj1IHWgDQhYHCsjbMErnufWpWl6YIA6cDr7VTieRiu6QsqghQf4R6VOhPlD5RknP0oAsmZ2cH+Hb+Ap8LFuMkZ6VU2ng5GSfy96swIRtH8Oev8AWgC6iuzAL6561Z2jaNuQD1Jqlu2BUIwQ3Wp925WyT7GgC4nl4OxTx3qdRGxVgeh71TgYgbC24dAMc1ZUq7lm+UAY2jtigDf8OWLXd8qvgh+MDoa9x0bZplnGr4BRcceleT+Ep4rNfNZR0J3HtXWNq0k6hkbOew9KAOwudeaRjGHIP8PpWbLrMmc+YdvQA9zWELoYHB5P3e34VHczIqb4znJGGx0oA6E645XazsGA4AqO51ESRh924bcN9a5WW9XeFV8oeufWmPekIxAHB6A9frQB0D365HoFAIY9/aqU84cOdwyOCPX2rn5L8Zwpw/qO1D3RYhpF+cD14oAfdyLJIcAll6YqnIEfdjd7ilE0s53xkIy9SO1Qzv5ry7sgAckUAQu6EBWJUdAR39qVZiXQDcWDY57VWYblQEnJPTuKliJ8w8nIOCB3oAsBiWUZyoHXHJ571cQ/Z5VWQgAdFX3qoY2il2yj5yAwx0Ue/vViFQ5B+8567qAO48Fp5l4QsnDcqzD9DXsOkQmOMFiuAdo5/irx7wPGyspUAhzuc/TtXr2mqPLwqZUnGT1FAG55mEwVZMnFJNJ5kfyEuONwqOGdowmCNx4we/NJfT/OoZODj7vYetAHP65PsRnKAF1YACub+E0hfxrrWe1nFgf8DatbxHcEQybV9QD6D1rnfg26t4814JN5oFlFkjsfMagD5S+NGP8Ahbni4+mpzfzrkomCuOnvius+NGf+FueLv+wnN/6FXHqNpIIoAvIwBPPGKcjsFJZuM1VRtmMnkfyqVD1KnJP6UAXI2XHzDJPHNWkILbA5A7Y6VRQgDdnnHANWYeeeh/SgC3ku4zkFR8vpVi13Ow46dKpkjgDsck5xmp0kIOB7YAoAv27vG/mKuSOAfSp4Y327gdrk7txqtEMk55J9DxWtbRuSHVCxyCM9CKANfRTIUw5POeO1dPp8XmFEAPIyAD2rE00eW7P03Dp2U1tWnmJcw/K3T5ccUAaPm8AEElTheO3vVW4mMaMFbCnqfWlmdogNv3jy2O1VSYp5PLedLdCpO9hkEjtQBXZzGSAQzHqcdRUTsct5I+U8jNT2oilC+fGwxxkelNYB5W2EbRwvsKAKkyBYlK/N3LDsadDhRwzFif4qsJn5kVhlj6d6iu8RKvzHjjgc0AKFw26MNk9x0zUU7qvzLuyvBHqaR5RFECcr34qpNchuXcBA3LY6mgBHkH3gGXccHFSysAFMXAUcsO5qjNMrNgbgpPQULIwZcHAxymeKALqOyKcuW4xx3NaFqeQz/TaOmayYgGZpNzBcbdvtWppcgZ403fJ0VscZoA9T8HQqsKvklcZI7g+lel6XIwVCjZB4Y+tcD4VVVtlTbySMn0rvLHiBFB4UjH/16ANOY+XGmPmZQeMdDVa/kMiKHJX/AGR6VM0h2kjG7PI/vVRvZiUTaegxn0oA5XxPfDyJEhbawBGD/Oud+A1wJviB4jAGCtlF07/vGq34vcJDKY8Z53YPOfWsL9m5mbx94nJO7/Q4ef8AgbUAfOfxp/5K54v/AOwlN/6FXHg9MDjqa7D41Y/4W54v/wCwlN/6FXG56dfpQBOGDdR8tPX/AGflGOtRKU56/SpIyScKRk0AWlYAghclRzVmEqVBYkEDII/lVON36gA4H3qmzyNpGTg/jQBbIDKVBxjnP9KltUYY819oH61VRiWJIzVpMspA6DHWgDSsipkwDxg4+tdJpownX5yM5PYelcxYMSQOFCdyOtdJZygxrwOoANAHRWcW8A9+ufU1qJIrR+Zksw+X6VjWzBYwWLdzkGr5lV3GHwSv3FHX60AWrhywJX5cD8TVEqs3zqAI0688jPfFMa4cZaLAccBT0+lV4wrSFVG2TPPPH4UAaaMPKwnX7q8frUbRA/uyQctySakUD7CAGC4PDdfzquJDgJ8o9eKAJpSEBI4QfLkd/wAarPOHBBG4dmPp6Ux5pPKMSnfHnIUetULieNThsuDxwcYNACTyAOzMQwYd/wCCsyedQwUENnv2p1zcKWAGCV7e9Ut3Db1XcRnA/nQBaDEcqackq7HySqZGD71SWY71LNnHtjAqTdtYdVQ9CepoAuq+7e5Ygn8xW9oqf6ZFnb8+ML2Brm4GClmJJAGRn+tdF4bieS6jcjv1z/KgD2Xwy7RxAjkngA9BXcWMisu1cgdGx61w3hw52IQCQM7j2HtXYQSZBGP3hbI28A/X3oA0d6xDLt0GB7+lYWqXhkkJCYXPVTxmtJ23RFRIA49uPpXOahcBomXBwmQxxxkUAcR4xvFitpSAy7Qckn72fSoP2W5xN428SnOR9iix/wB/GrnfiHfbbd1JyOcc8jPetj9kzjxl4kCnKGxhI/7+NQB4P8a/+SueL/8AsJTf+hVxncdveuz+Nf8AyV3xf/2Epv8A0KuLFAEgJ4PfvUqE46YHrUAP4HtT1bC+uf50AWyQwGMYznAqaM4XJG4jp7VUiHTnGe/pVtMhcFuvcd6ALaIVCuwxu5A9B7VYjYkcDAxnnrVTJZQc5C8E56VPE+CcLlOwHagDRtdwwR06n61u2TRxgHgg447D3rm4ZMcDdzyAOla1u4SMqDkn34FAHTQzjeC3TbxjpVq3nUKd5x6A9/xrm4p2aPaX3H0FWYpcqcElOoP900AbrXCCLcOXb5Qey+9Vtwj4L5QH5ie1Uw4KErzgY69aYlwFf5cccbccUAbRnPlBFyQecilhaS4nCROpO0ls8AAVjSXIOF+YRHqoPWmSXSoGCtgt09cUAX7mZY2URyZxyx6ACsq5my+7ICg54OfxqvLesk6TbVkZWDGN+VYA/dPsehqDUL+O/vbi4S0gso5TxawcRxH0X2oAdLJGo3gkfN+LCmyyApnuD2qqX+YY5cfoKd/fbG0/zoAnhZWIIXI64PepFdxIVcgj1NUYpfmzgnsue1SLJt2oR8zHO6gDRR9xG44VewrpfCkrG/X5gTnj0rkUf5yASvHHvXQeHGJuFKpwTjFAHt2iSMqKepAye2fpXW2UgdxuPy4B9K4bSGDQxq+4lV25PSupgc+V8zFEXBz3IoA0bycLCWUAHrx/FzXK63eMmdr5Rlzg8D6VrX95iLKDag7981x/iK8jxIwjEYXomc/jQB5b47ut8qxxjO3P1x713P7I4C+MfEgwQTYwn/yI1eX+J7lpdSdiflx2/lXp/wCyMVbxl4lKbsGxhxn/AK6NQB4X8a/+SueL/wDsJTf+hVxVdr8a/wDkrni//sJTf+hVxVAD1OM805OvIqPoRTwen5UATjnkMA3TGKtQsT8hwMc81ST0wcg5zViMhjnHzA0AW0wCM/e7jtU0LPwdwznkCqqH5CTg54A9KmQlCxK7mHYUAaELEEY5xmp0ldD05zyBVEuGAyOo9akDqD8oPy9BQBqJcO3yYA74HarsM4WMIv3T0J9awBNsC57cgf41aimJTp7YHagDoIJCigspIXqvrTNxJYPlec+4FUElMcRCMQfXrmojMxcHeSp55PegC9LMQo4yfTOOPWqrzGTBJ3Njr049KhNwSSVXnPIHNQTSYRwCN3Yjt7UASSSsWJGMgY9hUAdectndz9Kr+cDkrnPv3qEOxY9kNAF9JgrDgFvr0qUyAlVYBs9W9azkcZA28everUMqqD8gbK4APY+tAFgzKq4DFk6BiOalSRmZQOg5ziqIdgu49AOfepEkG0YOR60AW2ffgkbgB+ddR4Tx5yfeyThR3FcfECzkKcH0Brr/AAu4F2p/5acYNAHsOiE7I0WXDkbnBGdo9K3/ADBHCMNubPCnriuY0llZY3lUMRyCO/1rWlc/MqzBTjJz1AoAku7gAlVJII5DHpXBeKrwGMr84xwG9/eukvLzcNsinaFzuPH41554vvCtu4eQszcH2oA4LU5g925LYOTnPSvZf2QyT4x8S85H2CH/ANGNXhtwxc5YhsdPevb/ANj8EeMfEue9hCRn/ro1AHiPxr/5K54v/wCwlN/6FXFV2nxr/wCSueLv+wlN/wChVxdACg05Tgg0ylFAFgFu3GetSh0ClV61VDY6HmpVY449cnigC0jhl47DnNWYpAdgAxzVFJsDlRjPPuaspKAPugk+lAFzcCSW5YntTJGZSBkkjqageVwpQcA4zxyajkdl6cntnvQBaLjjYMDuSatQyBAdp6DJz3pmpxabFa6fLp17NczTITdwyxhfIbPAB75qrHJnLdePumgDW8/I5bGetNZtxyxOAe1UGuAqg4Iz6UNJ8mS+O+B3oAuvcbD+7O0Z4Pf8aryylpAUb5R6jrVUyA8gYz1INR78scdc9PWgC1JKXUBu/TFRrIuSV4x0J61Cz5Gcn0x60Atgdz2Xt9aALETsGL5+XofUVKjMV+XHoB6VVGMYP8u9TRuN27pnsaALBcE85G2kjkZnyCM+naoQ4y2c4PUe9KCTgAYHcjrQBdidlYjHB64rr/Crf6QEVxxyBXFw7SflBUYzyeorsPCP+v4A2dcnrQB6/pDqLTLEswUEEnrV+6mQBVQ7twySR0xXO6e4jZeVyAMgnpVye5DIy5bCjKkDv6GgBuo3KsjxuCzsNobPAHtXl3jO8+WVF3MxUKT3Fd5qt2pgyEIXIJH+FeW+MJ90zFTjJ5A7e1AHPGUqzA8LjvXvP7Hxz4x8S8k/6BDz/wBtGrwGMlyVOD65r3z9joAeL/EoAx/oMPH/AG0agDxP42f8lc8X/wDYSm/9Criq7X42f8lc8X/9hKb/ANCriqAFpQcUlFADs/Snq4A4qLNOzQBKrgckVMkoGC2Riqw9qVec5PSgCwWJYknJbng0gf7pA4H51FzkE8Z7UhJ644oAnjIySx5PX3qzEyoGPOf5VRhIByTVpCeSw564oAmL8ZUYU8kGo3l+UAcgmoXcAck+4FNZjxnHqAKAJC+cjoaGYhQQcZH41BuPGT9fanbzgAkHHSgCY7tqk/dH86duwSATu9e1RmRWQLjC5zj3pqsDnnOO+OlAFpWyF7Z4IqQ5CtvYE57VVD/JlsFu5p6yZVc8J0570AToxJ2gfN709OSST/8AX9qiLBU6YzwPU0K2CANu7OT7UAXQ4ypDYLdK63wpMxnXA2jrk/xGuKiJ34Oce1dZ4ZZlkJBHqBigD1GwcYDR4bafmz0q9JK3lAlepzkfyrJ091Ee5vlXHOe5qeeRIouXJGc5A4NAGbrF24jkXIBDZVscj8K8v12dZLj5Bz3ruNZud2/HDbuCRXnurktdEnhR93b0JoAqoxYBQcLnIOOle+/sef8AI4+JR0IsYf8A0Y1eARggrjkHOTXv/wCx4QfGXiYr0+ww8/8AbRqAPEvjZ/yVzxf/ANhKb/0KuKrtfjZ/yVzxf/2Epv8A0KuKoAWijtRQAUA0UUAL+NOHT0NMp+cgA9B0oAcrfOCyhh6GlfhuAVU8gdcVGfWnEkn39aAHqQP8TUgYu3y5GRyfQVBkE04Pkk/hQA8Ec9x2qNjnoaGOfb0poP5UAKDn0zTm4A5BPp6VGKOtAEmeDT1PGScD0qHPYdaeOo9aALCEnI4+tOAz6EjvUKsccngVIrbVyp6GgCZVZlIHSpHMZwI8qAOSepNVvMwQck+/pSF2A5II9KALcbhSM5A/vY610/hiVTdZUAMDxz1/CuQjcnaO3euh8NSbb3fkcHAPagD1mylXYNzjYe/v7UXVxmMoV5HTHU1l2M6LEN4GOox2NRTXK5c7iXzkFqAKGrTH5uBk9QR0FcJendcuSfmzkZrrtUn3RNuyc5JNcbcMxnJDbgO9AD0VcZ5AJIxiveP2OTnxh4kPH/HjD07fvGrwfrEMZIJyf8a94/Y5/wCRw8Tcj/jxh6f9dGoA8U+Nn/JXPF//AGEpv/Qq4qu1+Nn/ACVzxf8A9hKb/wBCriqADpS0KcMDgH60UAFFFHagAooooAUUoOOcCm0UAOzzmjPc02lzQAuePWhtuflJIHrTc0UAHWl4pKKAFHtTgaZ06U6gB4bHNPDEnIPf9ai4Gadknjkn2oAkL5yWILd6RGywOOnb1qMdfT1pdwAGByKAJ4yOrcY6Vv6AMyKyjkHHP865wMM55J71s6M4EuSxIXnHrQB6Ba3AWBSv3wc7R/OnTSq4Plsu7IJPYVk28olwSxx1JHBq9Gwl+V+OmBQBm6lKoDgnduyCfUYrlnYiZsD5ccYrqtXU+UdiqjHt1B9/auW6THCgMD1zQAu/aAcYxxjuK97/AGNl2+MPE3XmxhP/AJEavBGbKbmIJI7Dmvef2M/+Ru8S5zn7DD1/66GgDxj42f8AJXPF/wD2Epv/AEKuKrtfjZ/yVzxf/wBhKb/0KuKoAKUUlFAC0UlKP5UAFFFFABRR7UUAFFFJQAtFFKMbTyc9qAEooooAKUE0lFACg05HaN1ZGwyng+lNFB4oAcWJJJOSTk0vemZoBoAepwc5rS0uZ1mGMEH8xWWD2qzYsROBkfjQB3dodyB1AbI+6TitKJh5eSw39PpXPaY+9d20luwzwPetmFyY8v3+XFAEOrnEWQcgepzXL7l3kjDc8mt/VciE46ZP5Vzblsj5RyetAEgIP3hwO47V71+xmMeL/E/Oc2UR65/5aGvn4nCgr17/AEr6A/Yxx/wl3ifb0+xRf+jDQB4z8bP+SueL/wDsJTf+hVxVdr8bP+SueL/+wlN/6FXFUAFFFFABQKKKAF60dqSigBaD0o9aTigBe9FJRQAv86KSjNAC0Un4UUALRQKKACiiigAooooAKsWn+uXHPv6VX7VNbAmQYODQB1enkhlKgfKMZ7GujgIKKQAmR0xXPaRHuUKylQRjBroFKiMAbeO3c0AUdY2m3cKCrY5FcnI+Dk5P19fSul1niFcNtI656CuZkHz8nJxQA0liODkjnivoL9i/P/CW+JsjB+xRcf8AbQ18+EFRxlRjg4r6D/Yt/wCRr8S56/Youf8AtoaAPG/jZ/yVzxf/ANhKb/0KuKrtfjZ/yVzxf/2Epv8A0KuKoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBaKSigBaKTNFAC1ZswC4HHJ71WqzZjLYYZT070AdTpo3svBIGP8AIrpIgBGpIMhI288GsHTMnaT/AAgYHpXQ20m6MOMkngkjpQBi658sJWMDA7n+Vcq7kMGB9gK6XX3znJ+g/qa5KRzu5Occ0AWCrBBk5U9s19B/sXDHi3xMM5xZRf8AoZr51DZOGGTjrX0R+xWc+K/Exxj/AEKL/wBGGgCr8SvgD448QeP/ABBq+nQ6ebO9vZJ4i90FYqxyMjHFc3/wzV8Qv+eGl/8AgYP8KKKAD/hmn4hf88NL/wDAwf4Uf8M1fEL/AJ4aX/4GD/CiigA/4Zp+IX/PDS//AAMH+FH/AAzT8Qv+eGl/+Bg/woooAP8Ahmn4hf8APDS//Awf4Uf8M0/EL/nhpf8A4GD/AAoooAP+GafiF/zw0v8A8DB/hR/wzT8Qv+eGl/8AgYP8KKKAD/hmn4hf88NL/wDAwf4Uf8M0/EL/AJ4aX/4GD/CiigA/4Zp+IX/PDS//AAMH+FH/AAzT8Qv+eGl/+Bg/woooAP8Ahmn4hf8APDS//Awf4Uf8M0/EL/nhpf8A4GD/AAoooAP+GafiF/zw0v8A8DB/hR/wzT8Qv+eGl/8AgYP8KKKAD/hmn4hf88NL/wDAwf4Uf8M0/EL/AJ4aX/4GD/CiigA/4Zp+IX/PDS//AAMH+FH/AAzT8Qv+eGl/+Bg/woooAP8Ahmr4hf8APDS//Awf4VPbfs4fEKKQMbfSz9bz/wCxoooA3LL4C+PYlw9vpgHoLzP/ALLWmnwU8cLCF+zaaD6C8/8AsaKKAMjU/gF49uEKx22mZB4Jveo/75rF/wCGb/iFn/j30v8A8DB/hRRQAo/Zv+IQwfs+l5HOfto/+Jr2H9m34XeJfAGu61d+IorSOK7to44/In8zLBiTnjiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A retrograde pyelogram of the right kidney demonstrates reflux of contrast material into distended tubules in medullary pyramids, producing the characteristic brush lesion of medullary sponge kidney.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_5_14431=[""].join("\n");
var outline_f14_5_14431=null;
